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Chronic insufficient sleep affects basic physiological processes and increases risk for 
various mental and somatic disorders. Despite the growing number of omics-studies, sleep 
laboratory studies conducted in human samples, as well as various experiments in animals, 
the biological mechanisms underlying the health consequences of curtailed sleep are not 
fully understood. This thesis was inspired by the hypothesis that the consequences of sleep 
loss may be reflected as changes in the epigenetic processes, with DNA methylation 
(DNAm) selected as the most feasible to study. The aim of this thesis was to elucidate 
biological pathways associated with chronic insufficient sleep, as well as to explore how 
transient and reversible DNAm changes triggered by sleep loss are. 
In the first study, a cross sectional genome-wide DNAm analysis (Epigenome-wide 
Association Analysis, EWAS) was performed in relation to self-reported insufficient sleep 
in individuals from a population-based sample and in relation to insufficient sleep (shift 
work disorder) among shift-workers from an occupational cohort. No genome-wide 
significant differences in DNAm were observed in cases versus controls. The study revealed 
that insufficient sleep was accompanied by the loss of methylation and DNAm alterations 
in genes enriched in nervous system development pathway. The karyoplot evidenced for 
several clusters of CpGs on various chromosomes, including a cluster of 12 CpGs on 
chromosome 17. The genes corresponding to these CpGs were previously associated with a 
rare genetic condition accompanied by disturbed sleep and inverted circadian rhythm. 
The second study examined dynamic DNAm changes in relation to recovery from a shift 
work disorder in the occupational cohort of shift workers across the genome. The results 
indicated that recovery during vacation leads to the restoration of DNAm and specifically 
affects genes involved in the activity of N-methyl-d-aspartate (NMDA) glutamate receptors. 
These findings provide evidence for the dynamic nature of human methylome and suggest 
CpG sites in genes Glutamate Ionotropic Receptor NMDA Type Subunit 2C (GRIN2C), 
cAMP Responsive Element Binding Protein 1 (CREB1), and Calcium/calmodulin 
Dependent Protein Kinase II Beta (CAMK2B) as putative indicators of recovery in a shift 





In the third study, we studied the effect of depressed sleep on DNAm in a sample of 
adolescents with comorbid depression and insomnia as compared to healthy controls. No 
genome-wide significant differences in DNAm appeared in cases versus controls. However, 
the top findings of DNAm analyses were enriched in the synaptic long-term depression 
(LTD) pathway, emphasizing the role of sleep in synaptic plasticity and the widespread 
physiological consequences of disturbed sleep. 
Based on these findings, it can be concluded that chronic insufficient sleep is associated 
with a specific DNAm pattern in blood leukocytes, evidencing for the systemic 
physiological wide-spread consequences of curtailed sleep. Some of these specific DNAm 
alterations appeared to be reversible, once individuals restored sleep during two weeks of 
vacation. Altogether, this thesis contributes to an understanding of the changes triggered by 
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Sleep is essential for our health. According to the recommendations based on population-
based studies, in order to promote optimal health adults should sleep 7-8 hours, and 
deviations from the recommended sleep duration are associated with an increased risk for 
various diseases [1]. Insufficient sleep is globally highly prevalent, often under-reported, 
spreads across all age groups, brings rather high economic costs to the society, and causes 
wide range of adverse medical and mental dysfunctions [2].  
The ’24-hour society’ and globalization have brought both technological and structural 
changes in worktime arrangements, meaning the increase of irregular worktime 
arrangements and shift work. Approximately 20% of the European workforce and 15% of 
the U.S. workforce are engaged in some type of shift work [3], [4] and are potentially at risk 
to suffer from insufficient sleep. Shift work disrupts both circadian rhythm and sleep 
homeostasis leading to increased risk of various health issues, such as sleep disturbances 
and shift work disorder (SWD) [5]. Considering such a large proportion of shift workers in 
the global workforce, the societal implications of the adverse health effects associated with 
shift work are estimated to be substantial. 
Technological advances have been made in ‘omics’ in the last decade, including genomics, 
epigenomics, transcriptomics, metabolomics, and proteomics. Genome-wide assessment of 
DNA methylation (DNAm) is now affordable and promising avenue to uncover molecular 
processes underlying complex disorders. Insufficient sleep and mistimed sleep have been 
shown to strongly affect cell transcriptome – both in rat models [6], [7] and in human cohorts 
[8], [9].  The effect of acute sleep deprivation on human methylome was recently 
investigated in the selected cohort of young healthy males at Uppsala University [10], [11], 
but the DNAm changes associated with chronic insufficient sleep in workers remain 
underexplored. The study of the epigenetic changes at molecular level could foster the 
assessment and enhance methods of prevention and cure of the long-term health risk 
associated with the chronic sleep curtailment.  
Human methylome is responsive to the environment, but its dynamics is still poorly 
understood. In particular, we still have limited information on the short-term changes in 






best of our knowledge, there are no studies of DNAm on sleep with longitudinal data. 
Moreover, the reversible nature of DNAm makes it a potential tool to predict and estimate 
the effect of environmental change, as well as to pinpoint specific molecules that can serve 
as important indicators of the environment-disease interaction.    
The major objective of this thesis was to identify deviating DNAm pattern in individuals 
suffering from chronic insufficient sleep. The first study (Publication I) included two cross-
sectional epigenome-wide association studies (EWAS) conducted in two complementary 
samples of cases and controls from 1) sub-sample of the population-based FINRISK and 2) 
an occupational cohort of shift workers. In 1) cases were selected based on the self-reported 
evaluation of insufficient sleep, while in 2) cases constituted shift workers with SWD 
symptoms, such as excessive sleepiness and insomnia. Both samples overlap in terms of 
common component – insufficient sleep, as SWD symptoms include excessive sleepiness 
and insomnia.  
In the second study (Publication II) we continued with the occupational cohort of shift 
workers and performed paired EWAS to investigate the effect of vacation on DNAm 
compared to a working period in shift workers with SWD and without. SWD, a common 
condition among the shift workers, results in reduction of sleep quality and quantity and has 
adverse consequences for health and work performance [12].  
In the last study (Publication III) we assessed the effect of disturbed sleep and depression 
on DNAm and explored underlying biological processes in adolescents suffering from 
comorbid insomnia and depression. This cross-sectional EWAS was performed in the 
patient cohort from the Helsinki University Central Hospital and healthy controls. Insomnia 
and depression frequently co-occur and share many features and molecular mechanisms 







2 Review of the literature 
2.1 Normal human sleep  
Sleep stages. Normal human sleep occurs in a regulated order of two main states: rapid-
eye-movement (REM) and non-rapid-eye-movement (NREM), the latter further divided 
into the light (N1 and N2) and deep (N3) stages. The NREM sleep stages are identified by 
the amplitude of the slow wave oscillations in the electroencephalogram (EEG).  N1, the 
lightest stage, is characterized by a lowering EEG frequency, while N2 stage shows slow 
brain waves with occasional bursts of the rapid waves. The deepest stage N3 occurring 
mostly during the first half of the night is also referred as slow-wave sleep (SWS) [14]. 
During SWS EEG is characterized by the high-amplitude slow waves, as well as by sleep 
spindles and ripples [15]. Sleep normally begins with N1 and progresses through N2 to N3, 
followed by a REM sleep episode. Such cycle of alternating stages repeats several times 
during the night and lasts approximately 1.5 – 2 hours.  A reversible, consolidated to one 
main phase, human sleep occurs during the dark period of the day [16].  
Sleep duration. The duration of sleep per day varies considerably in the population. The 
core determinator of sleep duration is genetic, although its heritability established from a 
recent meta-analysis of the twin studies appeared to be quite low, numbering 38% [17]. 
Normally sleep lasts between 6 and 8 hours per day; for instance, a self-reported estimation 
from the Health2000 population-based study conducted in Finland gave a mean of 7.51 
hours [18]. In addition to the genetic component, sleep duration is strongly affected by 
gender and age. Women reported to sleep 0.23 hours more in average than men. Among all 
participants, the group of short sleepers (sleep duration 6 hours or less) included 16.7% of 
men and 12.5% of women, while long sleepers (sleep duration 9 hours or more) included 
10.5% of men and 16.1% of women. Among 7,262 respondents, short and long sleepers 
numbered 14.5% and 13.5%, respectively. In regards to age, sleep duration is shown to 
evolve in a complex pattern: according to a meta-analysis representing 3,577 subjects aged 
5-102, objectively measured sleep duration significantly decreased with age [19]. However, 
the aforementioned population-based study showed a U-shaped relationship between age 
and self-reported sleep duration, possibly reflecting co-morbidities increasing with age or 






Two-process model of sleep regulation. According to the widely accepted two-process 
model of sleep regulation, sleep is governed by two separate but interacting processes: a 
circadian component C and a homeostatic component S [20]. Process C determines the 
timing of sleep and is mainly directed by the genetically driven internal clock located in the 
suprachiasmatic nucleus (SCN) in the anterior hypothalamus (reviewed in Section 2.2.2 
Circadian rhythm disruptions). Process S depends on the duration of the preceding wake 
period and accounts for a sufficient amount of sleep. During wakefulness homeostatic sleep 
pressures increases and is followed by a period of sleep. A prolonged wake period results 
in the prolonged recovery sleep that contains more SWS than a normal sleep [14]. The 
interplay of circadian component C and homeostatic component S defines the amount of 
sleep and its timing – a sleep-wake cycle. Any failure in this interaction results in 
insufficient sleep and in a feeling of tiredness in the morning, with these effects being much 
more severe, should sleep disturbances persist for a longer time.  
Sleep and plasticity. Plasticity is broadly defined as the ability of nervous system to change 
its structure and function in response to the environmental changes. Regarding synaptic 
plasticity, such changes refer to the selective activity-driven strengthening (long-term 
potentiation, LTP) or weakening (long-term depression, LTD) of the individual synapses. 
A theory linking synaptic plasticity with sleep was proposed by Tononi and Cirelli to 
suggest that restoration of the synaptic homeostasis is the fundamental function of sleep 
[21]. Synaptic homeostasis hypothesis (SHY) proposes that during wake, due to ongoing 
learning, the synaptic strength in many brain circuits increases mediated by synaptic 
potentiation and results in LTP. Such net increase in synaptic strength occurs at high-energy 
costs, leads to saturation and creates a need for synaptic renormalization. During sleep, once 
brain is disconnected from the environment, neural circuits undergo renormalization, 
meaning downscaling of the synaptic strength or pruning. According to SHY, our sleep is 
‘the price to pay’ for plasticity [22].  
A large number of studies in rodents and humans indicate that sleep plays active role in 
memory consolidation, which is thought to be based on the changes in the strength of 
synaptic connections, LTP and LTD processes [23]. According to ‘active system 
consolidation’ concept introduced by Jan Born [15], the neuronal replay of memories 
occurring during sleep accounts for the formation of the long-term memory. Originated in 






during SWS propagate across the memory networks and lead to the formation of the stable 
long-term memories in neocortical networks. Regarding synaptic plasticity, such 
reorganization of the newly encoded representation comprises strengthening of some 
synapses and weakening of others, as well as formation of new synaptic connections with 
neurons outside of this encoded representation. Thus, sleep promotes both synaptic 
upscaling and downscaling, which either mediate an increase in the contribution of the 
selected neurons to the memory storage or reduce this contribution. The process of active 
systems consolidation is consistent with SHY and is currently regarded as an integrative 
basis for sleep-dependent formation of long-term memory [15].  
Molecular regulation of sleep and wakefulness. The cellular processes underlying sleep 
and wake states were extensively investigated in the studies of gene expression changes in 
animals. Early experiments in 1970-1980s evaluated global changes in brain RNA and 
protein synthesis in relation to sleep and waking or sleep deprivation and found that both 
RNA and protein synthesis was increased during sleep and decreased in sleep-deprived 
animals. In mid-1990s, the studies of associations between sleep/wake and gene expression 
led to the discovery of Fos, NGFI-A and P-CREB - transcription factors involved in synaptic 
plasticity. These findings evidenced for major changes in the patterns of expression across 
the genome that could be triggered by transition of the brain from one state to another [24]. 
Indeed, a study of brain gene expression in spontaneously asleep, sleep-deprived, and 
spontaneously awake rats conducted by Cirelli et al. revealed that sleep and wake states 
were associated with different sets of differentially expressed genes and, furthermore, sleep-
related and wake-related transcripts related to different biological functions [7]. For 
example, wake-related transcripts included those involved in energy metabolism (GLUT1, 
mitochondrial genes), glutamatergic neurotransmission (Narp, Homer), memory acquisition 
and LTP (Arc, NGFI-A, BDNF), cellular stress (HSP, Bip), and transcription activation 
(Per2, NGFI-A, NGFI-B, CHOP). Sleep-related up-regulated transcripts comprised genes 
involved in LTD and memory consolidation (calcineurin, CAMK4), membrane trafficking 
and maintenance (Rabs, Arfs, NSF), transcription deactivation (NF1, Id2), GABAergic 
neurotransmission (dlg3, gephyrin), and positive regulation of translation (eEF2, eIF4AII). 
The presence of genes associated with translation during sleep suggested that sleep is not a 
quiescent state characterized by global inactivity. It may enhance the synthesis of specific 






Since acute sleep loss was found to affect broadly gene expression, could sleep pressure 
also drive genome-wide changes at the level of epigenetic regulation? Massart et al. 
compared DNA methylation and hydroxymethylation genomic brain profiles of sleep-
deprived and non-sleep-deprived mice [25]. The statistically significant effect of sleep 
deprivation on DNA methylation was observed in genes related to neuritogenesis (Rab11b), 
synaptic plasticity (Pcdh19) and glutamatergic transmission (Wnt5a, Dlg4). Largest 
changes in hydroxymethylation were linked to genes involved in the processes of cell death 
(Daxx, Tnf), neurotransmission (Nrxn1, Nlgn3), and cell signaling (Akt).  The study also 
explored transcriptomics of sleep-deprived mice and revealed strong changes in the 
expression of genes involved in synaptic transmission (NMDA receptors), circadian rhythm 
(CLOCK), and activity dependent signaling pathways (CREB1, CREM). These findings 
supported the hypothesis that in animals sleep, deprivation has widespread impact on both 
the brain transcriptome and methylome.  
2.2 Insufficient sleep  
According to self-reported U.S. data, it is estimated that the proportion of the short sleepers 
in the general population increased from 7.6% in 1975 to 35% in 2014 [26]-[29]. Unlike 
sleep duration, the prevalence of sleep disturbances at the population level is difficult to 
estimate. A self-reported assessment of 150,000 Americans found that the prevalence of the 
troubles falling or staying asleep ranged from 13.7% (ages 70-74) to 18.1% (ages 18-24) 
for men, and from 17.7% (ages 80 and older) to 25.1% (ages 18-24) for women [30].  Data 
from 2007 regarding the prevalence of the self-reported sleep symptoms (mild and moderate 
severe) revealed the following numbers: difficulty falling asleep 18.8%, sleep maintenance 
difficulties 20.9%,  early morning awakenings 16.5%, daytime sleepiness 18.8%, non-
restorative sleep 19.7%, and frequent snoring 31.5% of adults [31]. Epidemiological studies 
on sleep duration, sleep quality, and insomnia have shown that insufficient sleep is 
associated with various adverse health outcomes, including cardiovascular [32]-[35], 
inflammatory [36], [37], and metabolic diseases [38]-[40], cancer [41], [42], cognitive 
decline [43], and increased rates of mood disorders [44], [45]. Short sleep was also 
significantly associated with mortality, as found in the recent meta-analysis combining data 






The genetic factors underlying curtailed sleep have been investigated in twin and genome-
wide association studies (GWAS). From the twin studies we know that heritability estimates 
of self-reported sleep length varies moderately between 31% and 44% [47], [48], with 
similar numbers for sleep quality (44%) [47] and insomnia symptoms (28% to 48%) [49], 
[50]. The recent findings from GWASes based on UK Biobank data have shown that self-
reported sleep duration is a complex trait with a genome-wide single-nucleotide 
polymorphism (SNP)-based heritability estimated at modest 9.8%. The 78 genome-wide 
significant genomic loci explained 0.69% of the variance in sleep duration [51]. The GWAS 
on insomnia based on combined data from UK Biobank and 23andMe resulted in 202 
genome-wide significant genomic loci (956 genes) explaining 2.6% of the variance and 
SNP-based heritability numbered 7% [52]. This study revealed a strong overlap between 
insomnia and psychiatric traits: for example, the strongest genetic correlations were found 
between insomnia and depressive symptoms (r = 0.64, P value = 1.21E-71), followed by 
anxiety disorder (r = 0.56, P value = 1.40E-7). The findings both from twin studies and 
GWASes suggest that the role of genetic factors in sleep duration and insomnia is relatively 
moderate and large proportion of variance is explained by the environmental factors and by 
the interaction of genes and environment. 
The causes of insufficient sleep may include behavioral, social or work-related factors, 
circadian disruptions, sleep disorders, as well as poorly understood processes occurring in 
numerous somatic and psychiatric disorders. 
2.2.1 Curtailed sleep  
2.2.1.1 Voluntary sleep curtailment 
The timing, environment and constraints of sleep are different across the human societies, 
making upstream social and environmental influences on individual sleep sufficiency 
extremely complex. According to the social-ecological model, voluntary sleep curtailment 
results from different complex and overlapping factors that evolve at the individual, social, 
and societal levels (Figure 1). At the individual level, factors influencing sleep include 
genetics, general health, lifestyle, beliefs, habits, and so forth. For instance, in the urban 
environment, such daily routines as exercise and diet, use of technology, and lifestyle habits 






mentioned gender and age-related differences, sleep practices, choices and beliefs vary 
greatly: bed-sharing with infants, engagement in social events, daily naps affect sleep and 
to a certain extend overlap with factors from the social level [54]. One example of a 
biological factor influencing lifestyle and sleep would be a chronotype, a trait with a strong 
genetic influence, where from the twin study heritability numbered 49.7% [55]. Thus, an 
evening-type chronotype increases risk for social jet lag, which may lead to curtailed sleep 
and symptoms of insomnia due to imbalance of the sleep-wake schedule and the intrinsic 
circadian rhythm [56]. 
Home and family environment play important role in sleep, for example larger household 
size was associated with greater sleep insufficiency, as well as were marital statuses 
’married’, ’living with a partner’, and ’divorced’ [57]. Both lower socioeconomic position 
and low education level were linked to a shorter sleep duration in the study of 6,928 adults 
from California [58], though the study on relationship between income and insufficient 
sleep has given contradictive results, depending on the adjustments for covariates [57]. 
Several studies reviewed in [54] have investigated the association between sleep quality and 
neighborhood, showing that areas with increased crime rate, environmental noise and light 
adversely impact sleep. The relationship between work and sleep is especially important: a 
survey of Basner et al. [59] indicated that work was the primary determinant of sleep 
duration. Holding multiple jobs increased risk for short sleep duration, while self-employed 
respondents were less likely to be short sleepers. Unemployment was linked to a longer 
sleep duration but also to a larger amount of sleep disturbances. Working in shifts is a well-
known factor associated with the insufficient sleep and will be reviewed in the Section 2.2.2. 
The societal level includes several factors known to impact sleep, among which use of 
technology and globalization are particularly relevant ones. When in 2011 the National 
Sleep Foundation conducted interviewed Americans regarding use of technology in the 
bedroom, the results were striking: firstly, 90% of Americans used some sort of a device in 
bed, and secondly, the use of such devices as smartphones, laptops, video game consoles 
used in the hour before bedtime was associated with reports of difficulties to fall asleep and 
non-restorative sleep [60]. More studies supported this finding indicating that light emitted 
by devices negatively affects sleep [61], as well as certain mental engagement like video 
gaming can result in sleep disruption and reduction of the self-reported sleep quality [62]. 






family members and friends, commercial activities, such as online shopping, as well as work 
responsibilities, including 24/7 emails and business in various time zones, can considerably 




Figure 1: Factors contributing to voluntary sleep curtailment, organized in three levels, according 
to the social-ecological model of sleep.  Edited from [54] with permission from Elsevier Inc.  
 
2.2.1.2 Pathological sleep curtailment 
It tends to be the rule and not the exception that insufficient sleep results from a combination 
of extrinsic (environment) and intrinsic (biological) factors, and the relative contribution of 
work-, social- or disease-related factors are impossible to identify. However, the statement 
of “can’t sleep versus won’t sleep” may help to distinguish voluntary sleep curtailment from 
a sleep disorder, whereby insufficient sleep occurs due to inability to obtain or maintain 
sleep or due to mistimed sleep. This chapter focuses on those common sleep disorders which 
include insufficient sleep as a prominent symptom, and which are most often studied in the 
general population. 
One of the most common sleep disorders, the definition of insomnia (F51.0 in ICD-10) is 






sleep quality; b) the sleep disturbances persist over a one-month period and occur at least 
three times a week; c) insufficient sleep length and poor quality impair daily activities, and 
d) the affected individuals show worries about insomnia and its consequences [63].  
According to the epidemiological studies, the prevalence of insomnia varies depending on 
the study design, studied population and the definition used: the latest self-reported U.S. 
data from 34,712 adults gave an estimation of 27.3% [64], while in European countries the 
numbers varied from 5.7% (Germany) to 19% (France) [63]. Insomnia is found to be more 
frequently reported by women than men, and the prevalence is known to increase with age. 
In fact, insomnia represents an extremely common health complaint in persons aged 60 
years and older and is expected to expand rapidly in this group from 205 million currently 
to 2 billion by 2050 [65]. According to the International Classification of Sleep Disorders-
3 (ICSD-3), based on chronicity of symptoms insomnia subtypes include chronic insomnia 
disorder, short term insomnia disorder and other insomnia disorder [66]. By the definition, 
chronic insomnia lasts at least three months with symptoms occurring at least three times 
per week. The treatment of chronic insomnia includes pharmacologic agents, such as 
benzodiazepines and related drugs, as well as non-pharmacologic approach, for example, 
cognitive behavioral therapy [63]. Short term insomnia can be temporarily associated with 
a stressor and should generally resolve within three months.  
Insomnia frequently co-occurs with mood disorders, such as major depressive disorder 
(MDD) or anxiety.  A clear majority of individuals suffering from MDD also report 
insomnia symptoms [13]. According to longitudinal studies, chronic insomnia was 
associated with a likelihood of 2-3 times higher of developing a depression or anxiety [67]. 
Though the underlying pathophysiology of the link between depression and insomnia is 
poorly understood, it is known that two conditions share bidirectional relationship, with a 
stronger evidence for insomnia preceding depression. The longitudinal study conducted in 
a Finnish twin cohort of 18,631 individuals revealed that poor quality of sleep predicted life 
dissatisfaction (odd ratio 2-3), while life dissatisfaction did not consistently predict poor 
sleep [68]. In elderly persons, insomnia frequently co-occurs also with chronic pain, cancer, 
cardiovascular disease, and medication use [65].  
As adolescence is characterized by prominent changes in sleep patterns and increased 
vulnerability to mental disorders, the incidence of both MDD and insomnia simultaneously 






adolescents varies between 5 to 8%, with a cumulative incidence reaching 15-20% by 18 
years old. As many as 10-40% of adolescents report unspecific symptom of disturbed night 
sleep or significant daily sleepiness. These symptoms of poor sleep and depression are 
reported more frequently after the onset of puberty. The epidemiological studies also 
evidenced for insomnia preceding depression and provided similar numbers for an increased 
risk of subsequent onset of depression – two- to threefold [69].  
Obstructive sleep apnea (OSA) is characterized by repeated cessations of breathing during 
sleep associated with arousals with or without oxygen desaturations.  OSA is further 
characterized by reduced sleep duration, sleep fragmentation, and oxidative stress. The 
standard measure to define the severity of OSA takes into account the number of apneas and 
hypopneas that occur per hour of sleep, referred as apnea hypopnea index (AHI) [70]. OSA 
is a highly prevalent condition: a 2015 study in Switzerland estimated that 50% of men and 
23% of women had moderate OSA [71]. In the United States the prevalence has increased 
and numbered 24-26% in men and 17-28% in women of 30-70 years old age group, with 
the proportion of affected individuals increasing with advancing age and increased body 
mass index [72]. Despite being such a common condition, OSA remains underdiagnosed, 
with approximately 82% of men and 93% of women remain unidentified [73]. The reported 
symptoms vary considerably, but snoring, daytime sleepiness, fatigue and witnessed apneas 
are the most common complaints. Patients with severe and moderate OSA are at higher risk 
to develop various comorbid conditions, such as stroke, myocardial infarction, 
hypertension, diabetes, arrhythmias, and depression [74].  
EDS is reported by approximately half of the patients with restless legs syndrome (RLS), 
a common sensorimotor disorder characterized by an urge to move and uncomfortable 
sensations in the legs worsening during rest and at night. Other sleep disturbances of this 
group include difficulty falling asleep and frequent night awakenings and can affect quality 
of life severely enough to warrant treatment [75]. As estimated from the community-based 
samples, the prevalence of RLS ranges from 7 to 23%, with an average of 10%, making it a 






2.2.2 Circadian rhythm disruptions  
Circadian rhythm. The circadian rhythms are near-24-hour oscillations found in virtually 
every physiological process in the human body and brain. The cluster of ~50,000 neurons 
within SCN termed as master clock coordinates tissue-specific rhythms according to the 
light signal from the outside world [77]. The photic entrainment originates in the eye and 
involves a conveyance from a small fraction of retinal ganglion cells containing light 
sensitive photo pigment melanopsin via the retinohypothalamic tract to the SCN [78]. 
Furthermore, the light signal passes from the SCN to adrenergic fibers innervating the pineal 
gland which regulates melatonin synthesis [79]. The circadian rhythm is entrained mainly, 
but not solely, by light and in healthy humans this intrinsic circadian period lasts slightly 
longer than 24 hours [80]. Each day master clock resets the human daily cycle in accordance 
to the daily cycle of light and darkness, therefore circadian rhythm is established by both 
internal master clock cycle and earth’s day/night cycle [81].  
At the level of individual cells, molecular rhythms are generated by interactive positive and 
negative transcriptional-translational feedback loop involving transcription factors. The 
positive loop is promoted by the heterodimerization of CLOCK (NPAS2 in vasculature 
tissue) and BMAL1. The resulting heterodimers bind to enhancer boxes in gene promoters 
and activate transcription of the clock-controlled genes encoding CRY and PER proteins. 
The latter ones accumulate in the cytoplasm during circadian cycle, eventually dimerize, 
travel to nucleus, and repress own transcription, thus acting as negative feedback loop 
regulators [77]. Many other proteins – transcriptional cofactors, kinases, phosphatases – 
participate in the regulation of the core molecular clock. Unlike genes regulating sleep 
homeostasis, circadian genes are widely studied and well characterized.  
Sources of circadian disruptions. Circadian rhythm is governed by both genetic and 
environmental factors. Chronotype or circadian preference defines individual’s preferred 
timing of sleep and wake and is independent of the environmental factors. We commonly 
separate individuals into the morning people (“larks”, prefer early sleep timing and early 
waking), evening people (“owls”, prefer later bedtime and later waking), and intermediate 
types falling between the two extreme types. There is a great variability in circadian timing, 






variation is known to contribute as much as 50% to a population variability of the 
chronotype, according to the twin and family studies [82]. 
While genetic factors may predispose to sleep disorders driven by circadian misalignments 
in a minority of individuals, the environmental factors affect a much larger proportion of 
human population. Certain changes in the environment can disorganize the circadian 
system, and since circadian system is intertwined with sleep/wake cycle, sleep may become 
a subject to disruption. The sources of circadian disruptions include those related to age 
(phase delay occurring at puberty) and ageing, particular disease states (comprising both 
common disorders, such as Alzheimer’s disease,  and rare disorders, such as Smith-Magenis 
syndrome, SMS, characterized by inverted circadian rhythmicity of melatonin), circadian 
rhythm sleep/wake disorders, changing photoperiods (seasonal disorders), jetlag, and work 
schedules (shift work, social jetlag, early starting times in schools) [79].  
During adolescence, the sleep patterns undergo changes: typically, teenager sleep is shorter, 
meaning later bedtime and early school starting time on weekdays and delayed due to 
various social activities. Both intrinsic bioregulatory factors resulting from puberty-driven 
changes and such psychosocial factors as bedtime autonomy, social networking, screen time 
and academic pressure push for a delay of the timing of sleep [83].  Many adolescents shift 
towards an evening chronotype and experience misalignment between own biological 
rhythm and social schedule, which results in daily fatigue and sleepiness, decreased school 
performance and behavioral problems.  
Social jetlag. Term ’social jetlag’ refers to the chronic jetlag-like phenomenon caused by 
modern work schedules and reflects the misalignment between internal circadian clock and 
actual sleep times during the week. Hence, as many as 87% of Northern Europeans show at 
least 1 hour of discrepancy between sleep time on workdays versus weekends [79]. This 
difference is especially pronounced for adolescents (and even more for those with evening 
type of chronotype), as bedtime tends to progressively delay during teenage years, both on 
weekends and weekdays, while morning rising is earlier on weekdays versus weekends. 
Such ‘living against the clock’ results in chronic sleep loss, and therefore social jet leg has 
been extensively researched in relation to the risks for cardiometabolic disorders [84], [85], 






Delayed sleep-wake phase disorder (DSWPD). According to ICSD-3 classification, 
DSWPD, a circadian rhythm sleep/wake disorder, can be recognized for the individuals with 
a complaint of insomnia and a chosen delayed timing for the major sleep episode. The 
prevalence of DSWPD depends on the population and numbers around 1% in adults without 
insomnia symptoms, as estimated from the population-based cohorts; however, among the 
adolescents and young people it ranges between 7 to 16% [88]. In the majority of individuals 
with DSWPD the circadian timing is normally aligned with the solar cycle, but the sleep 
episode is delayed resulting in chronic sleep loss. DSWPD commonly occurs among the 
teenagers due to such psychosocial factors as bright light during evening and night hours 
and late-night activities. The studies conducted in the young adults and adolescents also 
evidenced that the prevalence of moderate and extreme evening phenotypes is higher among 
the individuals with DSWPD [89]. 
Shift work and SWD. According to the Directive 2003/88/EC of the European Parliament 
and of the Council - Article 2, shift work is defined as “any method of organising work in 
shifts whereby workers succeed each other at the same work stations according to a certain 
pattern, including a rotating pattern, and which may be continuous or discontinuous, 
entailing the need for workers to work at different times over a given period of days or 
weeks”. Accordingly, “shift worker” means any worker whose work schedule is part of shift 
work”.  As night is the rest phase for humans, night shift workers are at a particular risk of 
circadian rhythm and sleep disruptions. Rotating shift schedule typically includes rotations 
of 3-day periods of early/ late/night shifts and rest days. Since circadian system is inert, such 
schedule does not allow the master clock to fully adapt to the night shifts [90]. Irregular 
shift work schedules, prevalent in the health care and transportation sectors, are less studied 
and suggested to have similar negative health impact, as night shift work.  
Both night (shift between 24:00-6:00 hours) and early morning shift work (starting between 
4:00-7:00) commonly result in insufficient sleep: according to the studies performed in shift 
workers, the sleep at night following the night shift is truncated by 2-4 hours and the loss 
involves N2 stage and REM sleep [91]. Up to one-third of shift workers add a compensatory 
daily nap which frequently exceeds an hour. Night work is also accompanied by daily 
sleepiness which often worsens in the early morning [92], [93]. Similar consequences, such 
as sleep curtailment and daily naps were observed in relation to the morning shifts, in 






awakening [94]. Rotating shift schedule differs in terms of the number of consequent shifts 
(speed) and the direction of rotation. Few intervention studies have shown that rapidly 
forward-rotating shift system (morning-afternoon-night) seem to decrease insomnia and 
daytime sleepiness, increase alertness, and improve work performance [95]-[98].  
As a result of circadian misalignments, a subset of shift workers are at great risk to develop 
SWD, a circadian rhythm sleep/wake disorder characterized by complaints of insomnia 
and/or excessive sleepiness temporarily associated with shift work and not explainable by 
another medical condition or medication use  [99]. After a longer recovery period, such as 
vacation, SWD primary symptoms likely ameliorate, and normal sleep/wake function 
should be restored. The prevalence of SWD varies and is estimated that one in five shift 
workers suffers from SWD. A relatively small population-based study reported that 14%-
32% of night workers and 8%-26% of rotating shift workers experienced SWD [100]. A 
study in oil rig workers in the North Sea estimated the prevalence rate of similar 23% [101]. 
Notably, the prevalence rates vary depending on whether ICSD-2 or ICSD-3 criteria are 
applied: ICSD-2-based prevalence of SWD among the hospital shift workers was higher 
and numbered 7.1%-9.2% (shift workers without nights), 5.6%-33.5% (shift workers with 
nights), and 16.7% (permanent shift workers) [102]. The vulnerability to experience SWD 
symptoms differs remarkably between the individuals, with age and gender known to play 
an important role [103]. In one of our studies in shift workers [104], we showed that genetic 
factors also contribute to the vulnerability to circadian disruption in relation to shift work. 
Precisely, a variant rs12506228 located downstream of the melatonin receptor 1A gene 
(MTNR1A) was associated with job-related exhaustion in shift workers and with changes in 
DNAm in the TSS of MTNR1A. 
In addition to significant costs to employers, related to decreased work performance and 
increased errors and accidents, SWD is linked to adverse health effects, including 
cardiovascular, gastrointestinal, mental, and metabolic disorders, as well as alcohol abuse, 
obesity, and psychosocial distress [100], [103].  
Jet lag. Like shift work, jet lag causes circadian rhythm and sleep disruptions. Jet lag results 
from the fact that environmental cues and light-dark cycle are in conflict with change of 
timing of the internal circadian clock and its symptoms are usually temporary and rather 






west. However, flight attendants are at particular risk to suffer from chronic jet leg, due to 
travel through multiple time zones and irregular work schedules. Thus, a study of 4,011 U.S. 
flight attendants showed that jet leg was associated with increased rate of sleep disorders: 
men and women had 3.7 and 5.7 times the reported prevalence, as compared to general 
population, but, surprisingly, the risk for sleep disorders did not correlate with the job tenure 
[105]. Smaller study conducted in female flight attendants found that transmeridian flights 
affect sleep quantity and quality: in particular, during the three days following the flight 
participants reported an increase in the number of awakenings, feelings of non-restorative 
sleep and sleepiness in the mornings, sleep restlessness, and difficulties to fall asleep [106]. 
A relatively recent study in the female flight attendants using both diaries and actigraphy 
indicated that these workers suffer from sleep disturbances, both in terms of sleep quality 







2.3 DNA methylation  
The term “epigenetics”, literally meaning “above genetic” or “in addition to changes in 
genetic sequence”, refers to the set of biochemical mechanisms which are not coded in the 
DNA itself and which result in heritable changes in the gene expression [108]-[110]. 
Though debates over this term continue, we usually categorize the epigenetic modifications 
into the three groups: DNA modifications, histone modifications, and non-coding RNA 




Figure 2: Epigenetic mechanisms of a human cell. Three levels of epigenetic mechanisms include 
the level of DNA covalent modifications, the RNA level represented by non-coding RNAs, and the 
protein level meaning chemical modifications to the N-terminal histone tails. Edited from [109] with 
permission from Springer Nature.  
 
At the DNA level, two types of chemical DNA modifications received the most attention - 
methylation and hydroxyl-methylation of the cytosine-phosphate-guanine (CpG) 
dinucleotides [111]. Histone modification occurs at the histone amino terminus and can 
affect gene regulation by altering the accessibility of the DNA sequence by transcriptional 
machinery [112]. RNA level encompasses various non-coding RNAs which exert effect on 






Epigenetics mechanisms are crucial for various organism functions and any misbalance in 
them can lead to the adverse health effects. Today, a wide variety of disease-associated 
epigenetic dysregulations has been reported for many disorders and behaviors.  This thesis 
focuses on the DNAm that, thanks to the technological advances of the last decade, is by far 
the most widely studied epigenetic mechanism.  
2.3.1 Creating a pattern  
In mammals, DNAm is achieved almost exclusively via addition of a methyl group to the 
5th position of the cytosine residue followed by the guanine residue. The methyl group from 
co-factor S-adenosyl-methionine (SAM) is introduced by one of the three enzymes 
belonging to the family of DNA methyltransferases (DNMTs) (Figure 3A). The human 
genome encodes five DNMTs, of which three are canonical enzymes catalyzing the addition 
of the methyl group to the cytosine – DNMT1, DNMT3A, and DNMT3B. DNMT1 
recognizes hemimethylated strand from the DNA replication and adds methyl groups to the 
cytosines on the newly synthesized strand providing mitotic heritability of DNA 
methylation patterns [115]. Both DNMT3A and DNMT3B come to the action after the 
global demethylation took place during early stages of embryonic development and perform 
de novo methylation across the genome [116]. Although such model suggests that DNMT1 
is responsible for the maintenance of the DNAm pattern, while both DNMT3 enzymes 
establish it after the global erasure, it is an oversimplification. Few studies mentioned in a 
recent review of Frank Lyco [115] have given evidence that all three DNMTs tightly 
coordinate the activity and are involved in both de novo and maintenance of DNAm 
genomic pattern. Interestingly, both DNMT3A and DNMT3B, but not DNMT1, can also 
convert 5-methylcytosine back to cytosine, acting bidirectionally as DNA 
methyltransferases and as dehydroxymethylases [117].   
The distribution of the CpGs varies greatly in mammalian genomes: in the bulk of genome, 
for instance, in the DNA repetitive loci, gene bodies or intergenic loci, as well as in tandem 
repeats of the centromeric, pericentromeric, and subtelomeric regions, the pattern exhibits 
low density and high level of methylation which is important for the genomic stability [118], 
[119] (Figure 3B). However, the most prominent feature of the vertebrate DNAm patterns 






end of the gene [120]. Approximately 1-2% of the total number of CpGs account for such 
CpG islands, which are typically DNA regions of 500 base or longer with at least 50% 
enrichment of GC content.  Exceptionally, CpG islands located on inactive X-chromosomes 
in females are known to be hypermethylated [118]. In addition to the CpG islands situated 
next to the gene promoters, some CpG clusters of unknown function are found between the 
genes (intergenic CpGs) or within the gene bodies (intragenic CpGs). Thus, of the nearly 
28 million CpGs present in the human genome, 20-40% are generally unmethylated, as 
compared to the remaining hypermethylated part [121].  
Almost 60% of the CpG islands are associated with the gene promoters and are 
unmethylated in the human genome allowing the transcription of the corresponding genes 
[122]. Already in 1975 two papers [123], [124] independently proposed that methylated 
cytosine in CpG can serve as a heritable epigenetic mark interpreted by the DNA-binding 
proteins and, by some mechanism, can ‘silence’ the gene. Technological advances in the 
last couple of decades have shown that, indeed, actively transcribed genes are associated 
with the unmethylated promoter sequences, however, such model of silencing is grossly 
oversimplified (Figure 3C). The majority of these studies focused on the effect of the 
methylated CpG islands located next to the transcription start sites (TSS) of the genes [122]. 
However, DNAm is context-specific and, for example, gene expression and DNAm in the 
first intron demonstrated quasi-linear inverse association across different tissues in fish 
[125]. Another controversial example is the function of the methylated CpGs located in the 
gene body. A study of Maunakea et al. [126] demonstrated that the intragenic methylation 
affects the transcription of the corresponding gene indirectly via activation of the alternative 
promoters. As much as 40% of genomic CpG islands do not co-localize with the promoters 
in TSS (so-called ‘orphan’ CpG islands marked as intragenic and intergenic CpG in Figure 
3B) but demonstrate similar promoter-like characteristics as promoter-localized CpG 
islands [127]. CpG clusters situated 2 kb upstream of the TSS (distal regulatory elements in 
Figure 3B), characterized by a much lower density of CpGs, and sometimes referred as CpG 
shores, are involved in the regulation of the gene expression in human cancers but this role 
is poorly understood [128]. Despite numerous correlative observations reviewed here, our 
expertise to assess the function of the methylated CpG at particular genic location remains 









Figure 3: DNAm pattern in mammalian genomes. A) Conversion of cytosine to 5-methylcytosine 
by DNA methyltransferases DNMT1, DNMT3A and DNMT3B; SAM, S-adenosylmethionine, a 
donor of methyl group, and SAH, S-adenosylhomocysteine. Edited from [129] and [130] with 
permission from Elsevier Inc. and Wolters Kluwer Health Inc., respectively. B) Genomic CpG 
distribution. White circles, non-methylated CpGs, dark blue circles, methylated CpGs. TSS, 
transcription start site. Edited from [119] with permission from Ivyspring International Publisher. 
C) Effect of DNAm at promoter CpG islands on the gene transcription, a simplified model. Gene A 
with unmethylated CpG islands at TSS is active with transcriptional state indicated by a green arrow; 
gene B with methylated CpG islands at TSS is silenced and repressed transcription is indicated by 






2.3.2 Modifying a pattern 
Summarizing the previous chapter, DNAm is a heritable, reversible, tissue and cell-specific 
modification that affects gene expression in a complex manner. Genomic DNAm landscape 
is relatively stable and needs to be preserved across the cell divisions.  However, unlike 
genomic sequence, DNAm profile changes through the life as a result of physiological 
changes, environmental influence, and disease-associated alterations (Figure 4).  
   
 
 
Figure 4: Major modifiers of human methylome – age, environment, and pathologies. The three 
factors are tightly related and inter-dependent resulting in an oversimplified schematic. For example, 
the widespread effect of genetic variation on DNAm characterized in recent studies of [132], [133] 
is missing here. Edited and reconstructed from [109], [134], [135].  
Ageing. The major physiological change in genomic DNAm pattern arises during early 
stages of development when massive demethylation occurring in the genome of pre-
implantation embryo serves as a starting point to establish cell-specific DNAm patterns 
[136]. Once established, such pattern is strictly maintained during cell division to sustain 
cell identity. Nevertheless, despite the same starting point, human methylomes diverge over 
the lifetime, with epigenetic similarities being lost even in the pair of monozygotic twins 
Ageing



























[137]. The age-associated DNAm differences accumulate, firstly, due to the phenomenon 
defined as “epigenetic drift” involving stochastic changes in baseline methylation levels, 
and, secondly, due to the directional and probably programmed changes in the specific 
regions of our genome. As an example of epigenetic drift, generally hypermethylated CpGs 
located in the heterochromatic regions of the genome, such as transposons and repetitive 
elements undergo loss of methylation [138]. An elegant comparative study performed by 
Heyn et al. [139] on the methylomes of newborns versus centenarians demonstrated that 
more hypomethylated CpGs were observed in virtually all genomic compartments of 
centenarians, for example, in regulatory regions, promoters, intergenic, both exonic and 
intronic sequences. 
Broad research of age-associated locus-specific DNAm changes gave rise to several 
mathematical models estimating biological age with astonishing accuracy. Thus, Horvath 
‘epigenetic clock’, a prediction tool based on DNAm state of the 353 CpGs across the 
genome, estimates DNAm age with an error of 3.6 years robustly across various tissues and 
cell types [140]. The gap between individual DNAm age and true chronological age that 
Horvath defined as age acceleration has been associated with various age-related 
pathologies, such as neurodegenerative diseases [141]-[143], and cancer [144], [145].  
Curiously, diverging from the early adulthood, human methylomes were observed to 
converge at the later stages of life. Recent studies of very old twin pairs [146], [147] gave 
evidence to a paradoxical phenomenon of ‘epigenetic assimilation’ meaning a reduction of 
epigenetic variability in very old individuals.  
Environment. The possible influence of various environmental cues on DNAm has attracted 
considerable interest. Starting from the groundbreaking study on the association between 
environment and methylomes of monozygotic twin pairs conducted by Fraga et al. [137], 
methylome divergence occurring due to the differences in lifestyle was also confirmed in 
the longitudinal twin study of Martino et al. [148]. Table 1 lists examples of association 
studies on some well-studied environmental cues and DNAm conducted in adult human 








Factor Tissue Phenotypic change/major finding Sources 
Tobacco smoke Lung, blood Lung cancer, inflammation, heart disease [149]-
[151] 
Air pollution Blood Decrease methylation in DNA repetitive 
elements with unknown effect 
[152] 
Asbestos Pleural tissues Ageing and susceptibility to different diseases  [153] 
Arsenic Tumor samples, 
blood 




Silica Blood Silicosis, lung cancer [156], 
[157]  
Benzene Blood Increased risk of acute myeloid leukemia [158] 
Ultraviolet radiation Skin samples Genome-wide hypomethylation, skin ageing [159] 
Alcohol consumption Blood Robust DNAm signature of a heavy 
consumption 
[160] 
Coffee and tea 
consumption 
Blood DNAm changes in genes involved in estradiol 
metabolism and cancer (women only) 
[161] 
Antioxidant and 
vitamin rich diet 
Blood DNAm changes in mismatch repair enzymes [162] 
Folate depletion Blood Global hypomethylation  [157], 
[163]  
Vitamins D, B 
supplements 
Blood No effect on long interspread nuclear element 
(LINE-1) methylation 
[164] 
Vegetarian diet Blood Disturbed methyl group metabolism [165] 
Caloric restriction Adipose tissue 
blood 
DNAm changes in genes involved in weight 
control and insulin secretion 
[166] 









Change of methylation status of MT-ND6. 
Changes in insulin sensitivity 
[170], 
[171] 
Endurance exercise Muscle biopsies DNAm changes in regulatory enhancers [172] 
Leisure-time activities Blood Moderate changes in methylation profile, 
cancer-specific pathways? 
[173] 
Early life stress Post-mortem 
brains. Blood. 
Suicide. Serotonin transporter SLC6A4 
affected. No robust findings. 
[174]-
[176] 
Socioeconomic status Blood DNAm changes in inflammation-related genes [177] 
Educational attainment Blood Low-education-methylome resembled one 
from a smoker 
[178] 
Table 1: DNAm candidate-gene and epigenome-wide studies of the environmental influences in 
adult human cohorts, studied tissues, and health effects (if known) or major finding. The chemical 
and physical environmental cues are extensively studied, as well as various nutritional factors and 
exercise. The studies on childhood adversity and socioeconomic factors are limited due to the low 
availability of the longitudinal studies. DNAm studies on sleep and shift work will be discussed in 






Pathological conditions. Due to rapid technological advances of the last decade, a growing 
body of studies has been published seeking out correlations between DNAm and disease 
traits. Figure 5 provides an overview of some common human disorders, excluding 
developmental syndromes and cancers, where modified patterns of DNAm have been 
revealed by the EWASes.  
 
 
Figure 5: Some common human diseases with studied DNAm patterns. The results are from the 
systematic PubMed search carried out 15-17 of April, 2020, with the following criteria: a) study 
conducted in 2010-2020; b) epigenome-wide study; c) case-control/twin study; d) array-based 
technology applied in study. For the sources marked in green, see Appendix. DNAm studies on sleep 
disorders are reviewed in Section 2.4.  
 
This systematic search presented in the Figure 5 was carried out due to two reasons. Firstly, 
I wanted to emphasize that exploration of the human methylome touched an impressive 
number of the most common disorders affecting humans. For couple of decades, DNAm 
analysis stayed far behind genome-wide association studies (GWAS), but once the 






publications in scientific journals. Though a typical EWAS cohort includes tens or 
maximum few hundreds of individuals, not hundreds of thousands as in GWAS, for such 
complex disorders, as schizophrenia or rheumatoid arthritis we already can find several 
studies performed on various cohorts of patients. EWAS might be still behind GWAS, but 
it is catching up rapidly. Secondly, just within the same disorder, we can observe a great 
variety of research questions, study designs and applied methods. For instance, if we look 
at the multiple sclerosis, we notice that DNAm studies include monozygotic twins 
discordant for multiple sclerosis and non-twin case-control study, the study performed in 
blood and brain samples, as well as the study where secondary-progressive and relapsing-
remitting individuals were compared with healthy controls. The titles of quite many EWAS 
studies involve words “signature”, “pattern” or “biomarker”. Growing larger in terms of 
sample sizes due to cost reduction, exploration of DNA methylome attracts researches from 
different medical fields, and study by study we are approaching closer in the understanding 
of molecular processes behind complex human pathologies. 
2.3.3 Exploring human methylome 
Epigenome-wide association study aims to reveal statistically significant correlation, but 
whether DNAm is causal in the pathogenesis of certain disease remains unclear. We also 
know that quite many of the specific environmental factors, such as diet, lifestyle habits 
(Table 1) are linked to the somatic and mental disorders. As such, DNAm variation can be 
affected by genetic variations, environmental factors, and stochastic processes of ageing and 
/or by all the above. Methods for genome-wide DNAm analysis include three major 
principles used to distinguish between methylated and unmethylated cytosines that are 
adapted for array-based-based platforms: restriction endonuclease-based, 
immunoprecipitation-based, and bisulfite conversion. The vast majority of the EWASes 
listed in Figure 5 were carried out using Illumina Infinium® HumanMethylation 
microarrays, and since all studies in this thesis were performed on 
IlluminaHumanMethylation450 array, I will focus on this assay in the section devoted to 






2.3.3.1 Genome-wide DNAm profiling using Infinium® technology  
Based on the Infinium® Technology, Illumina Infinium HumanMethylation450 BeadChip 
(450K) contains 482,421 CpG sites, 3,091 non-CpG sites and 65 random SNPs targeting 
26,658 CpG Islands in 21,231 genes, with a global average of 17.2 probes per gene [179]. 
The validation studies, following the release of 450K assay in 2011, confirmed a strong 
correlation with an assay of previous generation, Illumina HumanMethylation27 BeadChip 
(27K), as well as high concordance between biological replicates [179], [180]. The 
correlation values between 450K and whole genome bisulfite sequencing data numbered 
95%, indicating that data generated by the new assay are consistent with the results from 
the ‘gold standard’ of DNAm measurement, whole genome bisulfite sequencing. 
Considering that DNAm changes are typically mild, manufacturers emphasized that 450K 
array is capable to detect the differences of 20% in methylation level with 99% confidence. 
Though in 2015 Illumina 450K was followed by a larger version, 
IlluminaHumanMethylation850 (‘EPIC’), it remains the most widely used Illumina array in 
epigenetic research as the best compromise in terms of costs, sample throughput and 
coverage. 
The foundation of the Infinium technology is the assessment of cytosine methylation at the 
CpG site through quantitative genotyping of the C/T polymorphism generated by the 
bisulfite conversion [181]. Whereas 27K was based on a single type of assay (Infinium I), 
its extension 450K is a hybrid utilizing two different chemical assays Infinium I and 
Infinium II (Figure 6A). Such two-probe or, in fact, two-assay design results in divergence 
between methylation beta-values retrieved from Infinium I and II assays, leading to a 
specific type II bias during analysis [182]. To overcome this issue, several within-array 
normalization algorithms, along with the specialized steps for preprocessing, were 
developed as 450K analysis pipelines and further integrated into R software packages 






Figure 6: Infinium HumanMethylation450 BeadChip technology and data preprocessing 
pipeline. A) Infinium hybrid assay used in 450K array. Infinium I (27K) utilizes two beads per 
CpG probe, methylated and unmethylated, sharing the same color channel. To extend 27K array, 
a second assay type was added. Infinium II uses a single bead and two color channels. Due to the 
particular probe characteristics, i.e. CpG density within the probe, assays show different dynamic 
ranges, creating divergence of beta-values and type II bias during analysis. B) Illumina 450K 
preprocessing pipeline. Freely available R packages for 450K data preprocessing include 
methylumi, minfi, wateRmelon, ChaMP, and RnBeads. The R package minfi is used in this thesis. 






The typical pipeline for the processing of 450K data includes import of the raw data (IDAT 
files) and quality control procedures aiming to assess the success of the bisulfite conversion 
and array hybridization steps. Next, importantly for the hybrid design, within-array 
normalization is performed, comprising background correction and adjustment for type II. 
Over the past years few methods were developed and successfully validated in cancer cell 
lines, for instance,  ‘peak-based correction’ [182], Beta MIxtrute Quantile dilation (BMIQ) 
[184], Subset-Quantile Within Array Normalization (SWAN) [185], Sub-Quantile 
Normalization (SQN) [186], All Sample Mean Normalization (ASMN) [187], and data-
driven approach [188]. In all studies for this thesis, we selected SWAN, a method that was 
derived from normalization methods applied for the microarray expression platforms [185]. 
Validated in the kidney and rectum cancer cell lines, SWAN substantially reduced the 
differences in the distributions of beta-values derived from two assays, decreased technical 
variability between arrays, and, importantly, maintained sensitivity by showing a better 
detection of the differential methylation. Though SWAN was developed as a within-array 
normalization procedure, it is capable to conduct batch effect correction when comparing 
between arrays. Needless to say that other methods, such as ASMN, BMIQ and SQN 
demonstrated comparable performance in the evaluation of different pipelines and serve as 
valid alternatives for within-array normalization procedure [187], [189].  
Batch effects are widespread in high-throughput experiments and are critical to address 
[190]. Few possibilities to minimize or avoid them include a) application of supervised or 
unsupervised correction methods (reviewed in [183]), b) careful plan of a study design 
(described in detail in the next section), and c) adjustments for technical variables of the 
study, e.g. use of methylation array and slide as covariates in the regression model.  
The most common tissue for measurements of genome-wide DNAm is whole blood which 
is a heterogeneous mixture of different cell types. This presents an issue: in fact, DNAm 
profile observed from whole blood is a collection of the DNAm profiles from different types 
of the white cells. In order to explore how much the distribution of the different types of 
cell explain the observed variability in the DNAm, Jaffe and Irizarry [191]  conducted a 
study on publicly available datasets from Illumina450K platform. The authors found a 
strong evidence that cell types displayed larger variability than age, as well as confirmed 
that cell type proportions change with age and strongly correlate with global DNAm profile. 






from DNAm data, as described in the study of Houseman et al.[192], check for the possible 
confounding and perform adjustments for the cell counts in the regression model, if 
considerable confounding was detected.  
The last preprocessing step in the 450K analysis pipeline is probe filtering. Several types of 
CpG probes are typically removed from subsequent analyses: 
 probes that failed the hybridization step and showed detection P value > 0.01; 
 probes located on sex chromosomes (11,232 probes on X chromosome, 416 probes on Y 
chromosome); 
 cross-reactive probes (CRP) which are found to co-hybridize to various sequences and, 
thus, generating spurious signals (4400 probes) [193]; 
 polymorphic CpGs overlapping known SNPs, as DNAm detected for such probe can be 
affected by underlying genetic polymorphisms (16,770 probes) [193]. 
Typically, 7-15% of the probes are removed in the preprocessing steps and the final number 
of remaining probes is usually reported in the section describing methods of the study. 
The beta-value derived from the 450K preprocessing pipeline represents the measure of 
intensities of the umethylated and methylated status at the interrogated CpG site and ranges 
between 0 and 1 (Figure 6A). Another common way to measure the methylation level would 
be a logit transformation of bets-value, (log2 ratio of the intensities of methylated prove vs 
unmethylated probe), or M-value. Though beta-values are considered to be more intuitive 
for biological interpretation, they possess severe heteroscedasticity for highly methylated 
and unmethylated probes. In a comparison study of beta- and M-values [194], the M-value 
method demonstrated a better performance and statistical validity for conducting differential 
methylation analyses. Still, beta-values are widely used in EWASes and, for example, found 
a robust application in the clustering of methylation data [195].  
Summarizing this chapter, I would like to emphasize that development of Infinium platform 
resulted in an exponential growth of 450K data and made it an ideal choice for measuring 
DNAm. However, the challenges associated with the array design are considerable, and 
thanks to the extensive development of the various pipelines and software packages we are 
currently able to conduct EWASes involving hundreds of samples and make discoveries 






2.3.3.2 Steps towards a successful EWAS  
DNAm EWAS investigates the DNAm state at genome-wide scale in a sample of 
individuals and estimates whether differences at the CpG loci are associated with a trait. It 
would be natural to assume that conducting EWAS could follow similar principles as 
conducting GWAS, but several key concepts related to the DNAm phenomenon pose 
challenges and render design of EWAS conceptually different from GWAS. Firstly, though 
a given CpG site is either methylated or unmethylated, the DNAm in blood averages over 
millions of copies of DNA and what we measure is the percentage of cells that are 
methylated. Thus, DNAm measurement represents quantitative measure, unlike categorical 
character of genotype information in GWAS. Secondly, the dynamic nature of DNAm 
profile is an issue that we know very little about, in particular, our knowledge about time 
scale of these changes is still fairly limited. Thirdly, since DNAm is greatly affected by 
natural variation, we need larger sample sizes for EWAS than for GWAS, for any given 
trait.  Below I will discuss these and other crucial concepts underlying recommendations 
for conducting a standardized EWAS (summarized on Figure 7).  
 
 







Hypothesis. Starting with a hypothesis essentially increases the odds to obtain biologically 
interpretable results from EWAS. As commonly the research question involves DNAm 
changes associated with a disease, it might be useful to consider possible genetic risk factors 
and environmental exposures that modulate both methylome and risk for the disease. In this 
case, clearly outlined hypothesis covering all variables will determine the choice of the 
study design and selection of cohorts and tissue for the study [197]. 
Study sample selection. As mentioned earlier, large biological variability in DNAm 
necessitates to conduct power calculations in order to select a sample size large enough to 
detect small effects of DNAm on phenotype. The presence of confounders in the population 
is another issue in EWAS. Among the biggest influencers of DNAm are age, gender, 
genetics, smoking, alcohol consumption, diet, and medication [198]. Chronological aging-
associated DNAm changes have been intensively studied and for those I refer reader to a 
comprehensive review of Zampieri et al. addressing global reconfiguration of methylome 
during lifetime [118]. What is more surprising is that aging-associated DNAm changes can 
be identified in a population of the middle-age individuals with age range of only 9 years 
[199]. The research on sex-specific autosomal DNAm patterns has been so far inconsistent, 
though in a large meta-analysis McCarthy et al. identified sex-specific methylation profiles 
and particular autosomal CpG loci differentially methylated by sex [200]. Approximately 
20% of the inter-individual variation in DNAm is known to be attributed to genetics [201]. 
Smoking is known to affect DNAm profile and some studies on smoking-related changes 
in DNAm are mentioned in Table 1 previously. Interestingly, a study of Tsaprouni et al. not 
only identified specific loci associated with a smoking status (current smokers, ex-smokers 
and never-smokers), but also demonstrated that cessation of smoking reverses the effect on 
DNAm only partially, with some loci not returning to never-smoking DNAm levels even 
after 10 years [202]. Similarly, alcohol alters DNAm even at small quantities: a rather small 
study on 165 females indicated that alcohol use resulted in widespread changes in DNAm, 
though further pathway analysis of the genes corresponding to the affected loci did not 
reveal any significant results [203]. Dietary factors are pointed out in Table 1 and remain 
important influencers of methylome, but we rarely have precise information about those for 
a studied cohort. In the same manner, for a population-based cohort, use of medication is 
rarely fully reported, while in the selected patient cohorts such information will be most 






control for population structure and biological variability exist: a) to select a relatively 
homogenous population with respect to mentioned characteristics, for instance, to restrict 
age of participants and/or focus on one gender; and b) to adjust a regression model for 
known covariates, such as smoking status, alcohol consumption, genetic background, as 
well as age and gender if study includes a group of individuals of various ages and both 
genders.  
Tissue selection. Several studies addressed the tissue specificity of the DNAm pattern 
[204]-[206]. For cancer EWASes which stayed out of scope of this thesis, the selection of 
the appropriate tissue may be easier, though the purity of the sample and choice of control 
material remain problematic. For other diseases, due to unavailability of the disease-relevant 
tissues, the tissue of choice is commonly blood, which requires cautious interpretation of 
findings and validation of results. As mentioned in the previous chapter, the common 
practice is to determine the distributions of the different cell types in blood by methods 
embedded in the preprocessing algorithms and adjust for the cell counts in the statistical 
analyses. In this case the study sample needs to be large enough to permit statistical 
corrections for the six types of cells, calculated by the widely used Houseman method [192].  
Platform selection and batch effects. Choosing the right method for DNAm analysis was 
thoroughly reviewed in Kurdyukov & Bullock review [207] and extends far beyond this 
thesis. Illumina 450K is currently a good compromise of cost, sample throughput, and CpG 
coverage, but as any microarray technology it remains prone to batch effects and requires 
careful experimental design. Three issues should be addressed with particular care: a) 
balanced design, i.e. equal distribution of cases and controls between chips; b) random 
processing of samples, avoiding any possible groupings that may affect the measurement, 
and c) processing of all samples at the same time and under same strict conditions [196].  
Statistical analysis. Currently, consensus regarding the optimal data analysis approach for 
identifying differential DNAm in human cohorts is missing. Two major strategies include 
identification of differentially methylated positions (DMPs) and differentially methylated 
regions (DMRs). The methods to identify DMPs involve linear regression methods with 
control for confounding variables, followed by multiple-testing adjustments, for example, 
using false discovery rate. Due to variability of the individual DNAm measurements, this 






regions of contiguous CpGs associated with the disease. Thus, R packages minfi and 
bumphunter allow to detect DMRs, though the interpretation of the findings where region 
contains both hypo- and hypermethylated CpGs is problematic [198], [208]. Identifying 
methylation quantitative trait loci (meQTL) requires examining of DNAm, genetic variants, 
and expression data and enables to create a comprehensive map of relationship between 
epigenetic disease-related changes and regulation of gene expression [198].  
Validation. Among two possibilities – to use a different sample or a different methylation 
technique – the replication in a comparable but independent study sample is more common. 
However, using a different technique in the validation would be probably essential, as any 
errors or inconsistencies in the statistical analysis or technical failures of the assay might 
introduce same bias in both original and validation studies [196]. 
2.3.3.3 From DMP to biological pathway 
Similar to GWAS, next step after the regression studies and computation of P values for 
each CpG probe is the assessment of statistical significance and control of the multiple 
testing using Benjamin-Hochberg false discovery rate (FDR) or Bonferroni correction 
method.  Most commonly, the choice of the multiple correction method is made in the favor 
of FDR, since Bonferroni method is regarded as too conservative for epigenome-wide 
studies and calculated q value (FDR-adjusted P value) represents a good balance between 
the number of true and false positives [209]. The widely used threshold of statistical 
significance defining CpG as DMP is q value < 0.05 but other thresholds, such as 0.1 and 
even 0.3 can be considered.  Another parameter established from the association studies is 
hypomethylation or hypermethylation of the CpG which is estimated from the value of the 
beta coefficient in the regression model, with hypomethylation defined by a negative 
value. Next, DMPs are usually ranked according to P values or q values and mapped to 
genes using Infinium HumanMethylation450k BeadChip annotation data. From this step, 
two strategies to proceed with the interpretation of these results include study on individual 
genes (5-10 top ranked by statistical significance) and study on gene sets using pathway 
analyses applied to 10-500 top ranked genes. Both approaches are appropriate and 
frequently enrichment analyses are followed by the detailed research on individual genes 






Individual gene studies. The annotation data for 450K assay includes various types of 
information for each CpG that can be of interest for studies of gene transcription regulation. 
Few examples include chromosome and exact coordinate of the CpG, information about 
genomic location (Island, Shore, Shelf), location in relation to the gene and its transcription 
site (5’ Untranslated region (5’UTR), Body, 3’UTR, TSS200, TSS1500), enhancer status 
(True, Not available), and relation to promoter (Promoter_associated). In addition to the 
annotation provided by Illumina, the Ensembl Regulatory Build developed within Ensembl 
project provides a detailed overview of the regulatory activity of genome, for instance, 
predicting transcription factor binding sites, promoter, and enhancer for a given gene [210]. 
Ensembl genome browser is an annotation platform integrating tools and data resources to 
facilitate genomic analyses [211]. The possibilities of Ensembl platform regarding the 
studies of gene functions or association with clinical disorders are enormous; for example, 
in this thesis we explored in detail disease and phenotype data integrated from multiple 
databases and catalogues [212], e.g. GWAS Catalog [213], ClinVar [214], Online 
Mendelian Inheritance in Man (OMIM®, McKusick-Nathans Institute of Genetic Medicine, 
Johns Hopkins University https://omim.org), Mouse Genome Informatics (MGI) [215], and 
Rat Genome Database (RGD) [216].  
Gene set studies. Extending EWAS findings to pathway mechanisms underlying complex 
diseases has been and, perhaps, always will be a major challenge. Despite the absence of 
guidelines and common outlines and variability in results, the use of pathway-based 
analyses have grown exponentially in the last decade [217]. Furthermore, over 70 pathway 
analysis methods were proposed so far and, for example, once differentially expressed genes 
are identified, the selection of method includes both gene set analysis methods (also known 
as non-topology methods operating only with gene names) and topology-based methods. 
The latter require the input of other information, such as the direction of change (fold 
changes in gene expression analyses defining down or upregulated gene expression) or 
interactions between genes (activator/inhibitor) [218]. EWAS findings are limited to gene 
names, as our knowledge whether a hypermethylated CpG is associated with up- or 
downregulation of the gene expression is still limited. Thus, common way to proceed with 
the set of genes corresponding to DMPs from EWAS results is to conduct gene set analyses.  







Step Concepts, examples, and sources 
Study design  Two approaches exist 1) hypothesis-driven candidate pathway analysis with targeted a 
priori known pathways to assess and 2) genome-wide pathway analysis utilizing 
available data on extensive range of pathways, widely used in studies of complex 
diseases [217].  
Pathway 
annotation data 
Pathway annotation databases are roughly divided into freely available databases and 
commercial databases. Freely available are widely used due to easy access and 
transparence of terms and features. Prominent examples include Gene Ontology (GO), 
Kyoto Encyclopedia of Genes and Genomes (KEGG), PANTHER, Reactome, Biocarta, 
WikiPathways [219]-[224].  
 Commercial databases often offer user-friendly interface and pathway graphics but 
might require a significant investment. An example of a commercial pathway analysis 
tool is Ingenuity Pathway Analysis (IPA) [225] used in Publications I&III of this thesis.  
 Users of pathway databases need to be aware of the criteria used for inclusion in 
pathways, as well as update intervals. Simultaneous use of several databases for the 
same input data typically results in divergent results, due to the differences in 
annotations. The general recommendation is to use multiple databases and conduct a 
systematic comparison of the results obtained from the different tools [226].  
 One approach is to use an integrative web-based platform containing various gene-set 
libraries and embedded visualization tools, for example, FUMA GWAS and Enrichr 
[227]-[229] used in this thesis. Both platforms provide also tissue specificity and 
chromosome/location enrichment analyses. 
Input data A set of gene names is used as an input for genome-wide pathway analyses. The most 
challenging aspect is the number of genes serving as input. The minimum threshold 
appeared to be ten genes, while the upper limit did not exceed 400. Common way is to 
submit all genes with statistical significance < 0.05 (adjusted/unadjusted P values) or 
below other chosen threshold. Alternatively, input list may include all genes replicated 
in another dataset. Some studies seem to conduct pathway analyses with various 
numbers of input genes (100 – 400), in order to assess robustness of findings (reviewed 
in [217]).   
Statistical 
testing 
In the context of genome-wide approach, pathway enrichment tool utilizes competitive 
enrichment method based on one of the three analytical frameworks: threshold-based, 
rank-based or z-score-based.  
 The threshold-based, or over-representation analysis (ORA) uses hypergeometric, 
2 test to identify the pathways that are overrepresented among 
the genes serving as input [218]. ORA is used in all tools mentioned earlier.  
 The rank-based approach requires the genes to be ordered by the significance and then 
tests this ranked list for pathways having a lower ranking than overall distribution. 
Examples of statistical testing include Kolmogorov-Smirnov test and Wilcoxon rank 
sum test, approach is applied in GenGen and Gen Set Enrichment Analysis (GSEA) 
[217], [218].  
 Z-score-based approach is used in GSA-SNP and involves calculation of the deviation 
from a normal distribution accounting for the size of pathways [230].  
Post-analysis 
considerations 
Sources of bias to discuss include: a) gene set size – use of permutation and choice of 
threshold; b) correction for multiple testing – FDR or Bonferroni, if not too 
conservative; c) replication of findings in an independent data set [217].  






2.4 Sleep and DNAm 
There is a substantial evidence to hypothesize that DNAm is affected by sleep. Before any 
of DNAm studies on sleep were conducted in humans, a pioneering genome-wide study 
investigating the effect of acute sleep deprivation on DNAm was performed by Massart et 
al. in mice [231]. The discovered DNAm differences between sleep-deprived and non-
sleep-deprived male mice were enriched in pathways related to synaptic plasticity and 
neuritogenesis. Shortly after, acute sleep deprivation became the focus of several 
epigenome-wide [11], [232] and candidate gene-based [233], [234] studies.  All four studies 
were carried out in the same sample of 16 healthy young men and DNAm was measured 
following one night of total sleep deprivation (TSD). Just a single night of wakefulness 
resulted in several outcomes:  
 DNAm measured from blood is significantly affected by TSD across the genome in 
healthy humans. Precisely, 269 DMPs /119 genes with BH-corrected P values  <0.05 
were differentially  methylated in sleep versus sleep deprivation  [232]; 
 TSD leads to the tissue-specific alterations in methylome and transcriptome, with 
anabolic adipose tissue signature being different from a skeletal molecular signature, 
involving changes in clock genes CRY1 and PER1 (adipose tissue, hypermethylated 
promoter and enhancer region) [11], [234]. EWAS conducted in adipose tissue resulted 
in 148 DMRs with FDR-corrected P values <0.05, while no significant DMRs were 
observed in skeletal muscle after TSD; 
 TSD has an impact on lipid metabolism and has the ability to contribute to the 
development of obesity via changes in gene expression of liver enzymes [233]. In 
particular, three CpGs located in TSS region of stearoyl-CoA desaturase 1 (SCD) were 
significantly differentially methylated after TSD and the changes in methylation 
correlated with the activity of SCD; 
 TSD-affected biological pathways estimated from EWAS include metabolic fuel 
utilization, the Notch (genes NOTCH4, RING1, HES1, CCND1, MAML1), and Wnt 
signaling (CCND1, FZD8, FRAT1, FZD6, WNT4), with q-values <0.05 [11], [232]; 
 Correlation between the DNAm and gene expression was weak and required larger 






The focus of several DNAm studies carried out in larger population-based cohorts was sleep 
duration. Huang et al. [235] investigated genome-wide DNAm profiles in 173 young adults 
with short vs. long sleep duration and found 87 DMPs/52 genes with FDR-corrected P 
values <0.05. Furthermore, this study combined EWAS with assessment of gene function 
in Caenorhabditis elegans (C. elegans) and used a replication cohort for the DNAm 
investigation for genes whose perturbation affected C.elegans sleep. Though independent 
verification in a different cohort resulted in rather poor replication rate, the study revealed 
six genes with conserved roles in regulation of sleep duration in C.elegans and humans and 
proposed them as candidate genes for the future sleep studies (B4GALT6, DOCK180, 
GNB2L1, PTPRN2, ZFYVE28, NPY). A recent population-based study aimed to investigate 
the association of DNAm with sleep in 465 children using blood samples and 450K array 
[236]. Though this study assessed self-reported sleep problems, as well as sleep patterns 
estimated by actigraphy, the only significant association was found for DNAm level of a 
single module of nine genes and sleep duration. All but one gene from this module locate 
in the chromosome 17q21.31 region, with largest amount of sites annotated to MAPT  - a 
key regulator of Tau proteins in the brain. Earlier in a cohort of 351 adolescents, Jansen et 
al. [237] found that associations between DNAm in LINE-1, marker of global methylation, 
and sleep duration are sex-specific: both long and short-sleeping boys have lower 
methylation, than boys in the reference category, while girls have higher LINE-1 
methylation. Unfortunately, Jansen’s study utilized candidate gene-based approach and 
lacked evidence whether sex-specific changes occur at other parts of the genome.  
The only epigenome-wide DNAm study in monozygotic twins was performed for the twins 
discordant for diurnal preferences [238]. No global changes in the methylome were 
observed, as well as identified DMPs were only nominally significant, which might reflect 
the small sample size (15 discordant pairs). The GO enrichment analysis for 500 top DMPs 
resulted in over-represented terms related to cell adhesion and calcium ion binding – two 
categories essential for circadian clockwork.  
A relatively recent multi-ethnic EWAS on daily sleepiness revealed four genes with 
affected DNAm levels, however three of them were specific to African-Americans only 
[239]. This study utilized two main independent cohorts, a replication cohort of UK 
biobank, as well as SNP and gene expression data. The meta-analysis for two cohorts 






increase in sleepiness. Interestingly, of several associations found in EWAS, the only gene 
with observed correlation between DNAm and gene expression or sleepiness was RAI1, a 
gene involved in SMS and OSA, located at chromosome 17.  
Genome-wide DNAm in relation to narcolepsy was researched in two studies of Shimada 
et al. [240], [241]. A combined-rank approach for the top DMPs from blood samples [240] 
evidenced for 95% of hypomethylated probes and high number of sites located outside of 
CpG islands, with the top site corresponding to adenosine A1 receptor (ADORA1). The latest 
study on narcolepsy utilized DNA samples extracted from lateral hypothalamic and 
temporal cortical brain regions and revealed 77 DMRs, with the top association for myelin 
basic protein (MBP) in lateral hypothalamus [241]. In addition, authors reported that these 
DMRs significantly overlapped with DMRs found for the multiple sclerosis, indicating that 
two diseases might share partially their pathogenesis.  
DNAm patterns of OSA stayed in focus of at least six candidate gene-based studies and one 
EWAS (See Figure 8A for the references). However, the results obtained from the 
methylation studies on OSA may reflect more hypoxia, rather than sleep loss. Although 
latter is an important factor in the pathophysiology of OSA, the metabolic disturbances due 
to intermittent hypoxia are equally important.     
Overall, DNAm studies on sleep and sleep disorders number less than twenty (Figure 8A).  
In order to explore the associations between chronic sleep loss and methylome, we need to 









Sleep duration [235]-[237] Shift work status [242]-[246] 
Daytime sleepiness [239] Job seniority [247] 
Acute sleep deprivation [11], [232]-[234] Sleep quality [248], [249] 
Diurnal preferences [238] Maternal shift work [250] 
Narcolepsy [240], [241], [251]-[257] Tumor suppressors [249], [258] 
Obstructive sleep apnea [251]-[257] Clock genes [248], [259], [260] 
 
Figure 8: DNAm studies on A) sleep and sleep disorders and B) conducted in shift workers. 
Numbers in parentheses indicate: EWASes, blue; studies utilizing candidate gene approach, green. 
 
2.5 DNAm studies in shift workers 
There have been numerous studies to evaluate differences in DNAm profiles of night shift 
workers, as compared to day workers, in various occupational cohorts. To begin with, I 
summarize findings from four epigenome-wide studies, three of which have been 
performed in the cohorts of female nurses and one in the hospital-based cohort of mothers 
and infants. The pioneering study of Zhu et al. compared DNAm levels across 27K sites 
between ten female long-term night and day shift workers [242]. Despite a very small 
sample size, 4,752 genes, including CRY2 and CLOCK, showed differential methylation at 
P value <0.05 after adjusting for multiple comparisons, with two-thirds being 
hypermethylated in the night shift workers. Using IPA network analysis and all 4,752 genes 
as input, a pathway related to DNA repair was found featuring several cancer-relevant 
genes, including CDKN2A, BCAS3, and ESR1. Considering a large number of genes 
submitted for pathway analysis, small sample size, as well as the smallest Illumina array 
used for DNAm profiling, these results should be interpreted with caution. A larger study 















































and 65 day workers and found that 65% of the 473,800 tested CpGs were hypomethylated, 
indicating a systemic loss of methylation among the shift workers. The CpGs in several core 
circadian genes, including CLOCK, CSNK1D, CSNK1E, NPAS2, PER1, PER2, PER3, and 
RORA were significantly less methylated (FDR-corrected P values <0.05) among the night 
shift workers. GO enrichment analysis indicated that terms related to host defense and 
immunity were significantly represented among the genes corresponding to DMPs.  Though 
no cancer-related pathways were found from the enrichment analysis, such prominent loss 
of methylation genome-wide and, in particular, in circadian genes, may contribute to the 
increased risk of cancer. Several studies on transcriptomics indicated that alterations in the 
gene expression of circadian genes were associated with increased risks of various cancers 
[261]-[265]. Once Bhatti’s sample was extended to 197 females (111 night shift vs. 86 day 
shift workers) [246], EWAS resulted in no significant findings in relation to shift work 
status. The top findings were hypomethylated and corresponded to the genes linked with 
various cancers (BACH2, JRK, RPS6KA2) and type-2 diabetes (KCNQ1). Similarly, no 
significant DNAm differences were found in relation to the chronotype of night shift 
workers. The latest EWAS in relation to shift work was performed in placental tissue from 
237 participants who were engaged in night shifts work or not, and reported an overall trend 
towards hypomethylation among the top 57 DMPs [250]. Enriched GO-terms belonged to 
“cell-cell adhesion”, and notably, among the top 298 DMPs submitted for the enrichment 
analysis, the only clock gene was PER1.  
Candidate gene-based approach comprised two groups of genes that were extensively 
studied in shift workers: circadian genes and tumor suppressors. The findings of DNAm 
studies of circadian genes in shift workers have been consistent with the study of Bhatti: 
PER1, PER2, and BMAL1 showed nominally significant decreased methylation in night 
shift workers [259]. Furthermore, for instance a higher number of night shifts was associated 
with a decrease of PER2 methylation, while PER1 and BMAL1 methylation decreased with 
a longer lifetime duration of night shift work. However, once the sleep quality and sleep 
duration were included in the study of Bukowska-Damska et al. [248] as outcomes, adjusted 
for the shift work status and chronotype, the findings on DNAm levels of circadian genes 
became inconsistent. Thus, PER2 methylation increased among the morning chronotype 
day workers who slept 6 hours and less, and same occurred to PER1 methylation among the 






and shift work status resulted in lack of significant associations for other circadian genes, 
even though the sample comprised 710 women. It is plausible to assume that female shift 
workers represent a heterogeneous sample where job seniority, number of shifts per night, 
total night shift work duration and other factors affect DNAm in a complex manner and 
should be considered as potential confounders in DNAm studies. 
Circadian disruption in shift workers was hypothesized as one of the molecular mechanisms 
increasing risk of cancer. Of five studied circadian genes CLOCK, BMAL1, CRY1, PER1, 
and PER2, increased DNAm levels in breast cancer cases among the night shift workers 
were found in CLOCK, BMAL1, and CRY1 (all nominally significant associations), as 
compared to breast cancer-free controls [260]. None of these studies assessed gene 
expression, therefore results suggest that epigenetic regulation of circadian genes is rather 
complex and DNAm of clock genes may contribute to cancer development in shift workers. 
Regarding the tumor suppressors, no significant findings were observed in the study of 
association between sleep quality and DNAm levels of the selected tumor suppressor 
genes in shift workers [249]. In a recent study of Carugno et al. [258], however, night shift 
workers had clear reduction of methylation in ESR1, TP53, BRCA1, and BRCA2.  
2.6 Studies of DNAm dynamics 
The majority of existing EWASes are cross-sectional and unable to evaluate DNAm 
changes over the time and establish the direction of causality. Given the dynamic nature of 
the human methylome, longitudinal studies are ideal for capturing such dynamic changes 
that accompany progression of the disease or those induced by environment. However, 
today, only a limited number of longitudinal DNAm studies have been performed. A 
systematic search in PubMed conducted 11.05.2020 using key words ‘DNA methylation’, 
‘dynamic changes’, ‘dynamics’, ‘longitudinal analysis’ resulted in 351 studies. Of those, 
only studies conducted in human samples (adults or adolescents, N ), with epigenome-
wide assessment of DNAm changes were taken for further investigation. After removing  
a) twin studies, b) prenatal, development, early childhood studies, c) studies on ageing, and 
d) studies on cancer samples, 23 longitudinal epigenome-wide association studies 






The vast majority of these studies used Illumina 450K array (18 studies), three studies 
profiled subjects with EPIC array [266]-[268], and two studies performed DNAm 
measurement on 27K array [269], [270]. The number of profiled participants varied greatly, 
with minimum of six [271] to the biggest cohort comprising 1,344 individuals [272]. Half 
of studies involved less than 100 individuals, five studies included few hundreds but less 
than a thousand [266], [268], [269], [273]-[275], and six studies performed DNAm 
measurements of more than a thousand individuals [272], [276]-[280]. Replication in an 
independent cohort was carried out in six studies [273]-[275], [277], [279], [281]. 
Concerning the significant findings, all but one study reported individual DMPs or DMRs 
(significant after correction for multiple testing comparisons), with a single study exploring 
differentially methylated signatures and differentially methylated pathways [282]. In 
virtually all studies, DNAm analyses were followed by some type of gene set enrichment 
analysis, network analysis or clustering.  
Of 23, twenty-one study utilized paired design, one study measured DNAm at three time 
points [283], and one study profiled individuals across six sampling points [271]. According 
to the time interval between first and last measurement, I divided all studies into the four 
groups: 1) ‘very long‘, 11-12 years; 2) ‘long’,  5 – 10 years; 3) ‘short’, 12 months – 24 
months, and 4) ‘very short’, 1 day- 6 months.  
‘Very long’- term dynamics. Altogether four paired studies explored DNAm changes 
during prolonged time: two were concerned with chronic alcohol consumption [270], [279], 
one study was performed for the smoking status [278], and one - for BMI [280]. All studies 
in this group concluded that trait-associated DNAm changes occurred genome-wide, 
however, the amounts of modified CpGs are strikingly low.  Both alcohol consumption 
[279] and smoking status [278] assessed in large cohorts were accompanied by changes in 
300-400 DMPs (less than 0.1% of 450K probes). Both studies also estimated the 
reversibility of changes, for instance, authors of alcohol study mentioned 218 DMPs with 
100% degree of reversibility observed in former drinkers. Despite a large sample, BMI study 
resulted in 310 DMPs associated with BMI, but only 34 of them showed changes 
longitudinally after 11 years [280]. This study also lacked any assessment of reversibility.   
‘Long’- term dynamics. This groups of five paired studies assessed DNAm changes 






consistent with a ‘very long’-term study [278]: a small amount of significant distinctive 
changes in 22-52 CpGs and slow reversion of methylation levels to never smoker’s level 
during several decades after cessation of smoking [272]. The BMI study of Sun et al. [274] 
established causality in the relationship of obesity and DNAm, indicating that ‘obesity is 
the cause, not a consequence, of changes in DNAm over time’. Interestingly, causality was 
evidenced from unidirectional changes of only 25 DMPs observed after 6.2 years in the 
main and replication cohorts of totally 1,120 individuals. A large study of Ward-Caviness 
et al. [277] on the incidence of myocardial infarction combined three cohorts and explored 
DNAm changes in the range of 7-9 years. Nine DMPs defined as ‘epigenetic fingerprint’ of 
myocardial infarction were consistently revealed in two cohorts and further tested for its 
prediction in the third independent cohort. Despite modest results from prediction analysis, 
this is the only longitudinal DNAm study of cardiovascular condition integrating gene 
expression and metabolomics data. Last in this group, a study on anxiety disorders 
conducted in the cohort of 47 adolescents over 5 year follow-up detected four distinctive 
trajectories of DNAm changes according to the differentially methylated signatures and 
diagnosis [282]. In the persistent group (individuals suffering from anxiety at both time 
points), 27 differentially methylated pathways were observed (adjusted P values <0.05), 
accompanied by global hypermethylation in the central nervous system development 
pathway. Notably, the study used saliva samples from non-medicated adolescents of both 
genders and aimed to uncover gene ontologies, rather than isolated genes. 
‘Short’- term dynamics. The group of ‘short’-term dynamics included six paired studies 
and a study with six time points [271], all investigating changes occurring within 12-24 
months. Three studies investigated DNAm changes in relation to psychiatric disorders after 
one year follow-up: bipolar disorder (N=95) [284], conversion to psychosis (N=39) [285], 
and depression (N=59, adolescents) [281]. Perhaps, due to small sample sizes, the amount 
of statistically significant changes ranged from one to nine DMPs, with large amount of 
nominally significant results. Surprisingly to be in this group, two studies on 
neurodegenerative disorders – pre-symptomatic dementia [286] and Parkinson’s disease 
progression and medication [268] – revealed 8 and 138 DMPs, respectively, all corrected 
for age and assessed for overlap with Horvath clock [140]. A relatively small study on metal 
exposure and subclinical atherosclerosis in a cohort of 23 middle-aged men identified  






time point study’ involved six individuals profiled during long-term isolated environment, 
Mars-500 mission [271]. Despite a small size, phenotype synchronization algorithm applied 
in the study resulted in 5,326 DMPs (1.1% of 450K probes) enriched in pathways related to 
mood, circadian rhythms, and glucose state. Needless to say, longitudinal personal DNAm 
dynamics was earlier explored across 28 data points, measured over a period of 36 months 
in a 54-year old human volunteer with elevated glucose condition [288]. This study provided 
evidence for relatively slow DNAm changes, occurring 80-90 days prior to glucose 
elevation. Overall, personal methylome seemed to be extremely stable longitudinally, with 
minor changes taking place in regions associated with gene regulation.   
‘Very short’- term dynamics. This group comprised seven short-term studies, all of which 
were concerned with some type of distinct exposure: medication [276], [283], bariatric 
surgery [289], meditation [290], combat experience [273], [275] or acute alcohol 
withdrawal [266]. Both metformin [283] and fenofibrate [276] therapies, as part of clinical 
trials aiming to explore drug-induced alteration of DNAm profiles during one or three 
weeks, respectively, resulted in few DMPs affected by drug. Similarly, a study on adiposity 
state of normal and obese women before and after bariatric surgery identified two 
differentially methylated genes [289]. A ’meditation’ study was performed in a cohort of 17 
experienced meditators, profiled before and after a day of intensive mindfulness-based 
practice [290]. Surprisingly, 61 DMPs enriched in genes associated with immune response 
and ageing were identified, evidencing for very rapid changes in human methylome over a 
short time window. The study of Snijders et al. [273] compared DNAm patterns in three 
military cohorts before and after ~ 6 months combat exposure, in relation to the development 
of post-traumatic stress disorder (PTSD). Though majority of DMPs failed replication, the 
most prominent findings involved DMRs corresponding to genes, previously associated 
with PTSD in the longitudinal military cohorts [275]. Last for this group, a study of Witt et 
al. [266] investigated DNAm changes in 99 male patients during acute alcohol withdrawal 
and after two weeks of recovery, as compared to age-matched controls. A relatively large 
number of observed DMPs (2,876) witnessed for prominent genome-wide changes 
associated with withdrawal, mainly involving genes related to immune system response. 
Similar to the abovementioned study of Dugué et al. [279], the differences in DNAm levels 
between cases and controls diminished after the recovery, indicating partial reversibility of 






Common for all studies is the fact that outside of the early stages of development and within 
such a relatively short period of human life as a decade, human methylome is more stable 
than dynamic. Nevertheless, various environment exposures, lifestyle habits, as well as 
underlying pathological conditions modify DNAm inducing a limited amount of precise 
changes. According to some of these findings, certain modifications are reversible, for 
instance, upon cessation of smoking some of the DNAm changes are reversed to the baseline 
(non-smoker’s status) relatively fast and some take decades [278].  
 
*** 
The studies from the last two groups explored DNAm changes over short time intervals, 
similar to Publication II of this thesis. However, to the best of our knowledge, there is no 
longitudinal study which has examined epigenome-wide DNAm changes in relation to 








Our main hypothesis was that sleep loss induces systemic changes across the human DNA 
methylome. The goal of this thesis was to explore DNAm changes of blood leucocytes 
associated with curtailed sleep, as well as to investigate how transient and reversible such 
changes are.  
The specific aims for each publication were: 
1. to identify and characterize deviating DNAm pattern in relation to insufficient sleep.  
In this study, we used two independent datasets: the DILGOM cohort including 
individuals reporting insufficient sleep and occupational cohort of shift workers 
suffering from insufficient sleep as part of SWD diagnosis. (Publication I) 
2. to observe DNAm changes in relation to a manifesting circadian sleep/wake 
disorder, SWD, and the recovery from it. In this study, we used paired data from an 
occupational cohort of shift workers, in combination with sleep diaries and 
questionnaires collected during work and after vacation. (Publication II) 
3. to study the effect of sleep disturbances and depression on DNAm and explore 











4 Materials and Methods 
We used DNAm data (Infinium HumanMethylation450k), questionnaires, and clinical data 
from Finnish Institute for Health and Welfare (DILGOM, general population-based 
sample), Finnish Institute of Occupational Health (AIRLINE I and II, occupational cohort 
of shift workers), and Helsinki University Central Hospital (ADSLEEP, selected cohort of 
patients and healthy staff). Table 3 lists the sample datasets, basic characteristics of the 
participants, and the study designs used in each publication.  










II AIRLINE II 32 (43.8 ± 8.8) 78 Paired measurements 
III ADSLEEP 17 (16.0 ) 100 Cross-sectional 
Table 3: Sample datasets and study designs used in Publications I-III. SD, standard deviation. 
4.1 Study samples 
4.1.1 Characteristics of the participants, sampling, and study approvals 
Prior to the analyses performed in Publication I, we found that age and gender strongly 
affect the DNAm in that sample. From corresponding EWASes we obtained a) 25.6% 
(122,721) and b) 7.9% (37,780) of 479,954 CpGs with false discovery rate (FDR)-corrected 
P values for age and gender, respectively. Thus, two samples used in the Publication I 
(DILGOM and AIRLINE I) were matched in age and gender, leaving out all women and 
older men. In the Publication II, we included all subjects with paired data of both genders 
(AIRLINE II), as no replication sample was used for these analyses. Finally, ADSLEEP 
used in the Publication III included only boys with depression and sleep disturbances 
recruited from the Helsinki University Central Hospital Department of Adolescent 
Psychiatry. The healthy controls recruited from the hospital staff were all men, as well.  
DILGOM (I). Dietary, Lifestyle, and Genetic determinants of Obesity and Metabolic 






for cardiovascular and metabolic disorders in Finnish population [291]. The DILGOM 
population-based subsample comprised 517 individuals (54% women) aged 25-74 years, 
out of which 88 men aged 25-50 with available data on alcohol consumption and smoking 
status (FINRISK survey questions #115 and #87, respectively) were considered for the 
Publication I. After defining the exclusion criteria for the study of sleep insufficiency (see 
4.1.2 Phenotypes), we selected 79 men (age = 39.3 methylome-wide analyses. 
The blood samples were collected between 7 a.m. and 1 p.m., after a 10-hour fasting period.  
AIRLINE (I).  Forty-two shift workers from a Finnish airline company aged 27-60 (21% 
women) participated in the questionnaire-based study carried out in the Finnish Institute of 
Occupational Health [292]. All participants completed questionnaire on general health, 
working times, lifestyle habits including smoking status and alcohol consumption, and 
answered specific questions on insomnia and sleepiness. The shift work schedule included 
morning (shift starting before 6 a.m.) and/or night shifts (shift lasting at least three hours 
between 11 p.m. and 6 a.m.), in addition to the evening shifts. After the shift work disorder 
status was assessed (see 4.1.2. Phenotypes), we selected 26 men (age = ). The 
blood sample collection was performed between 7 a.m. and 11 a.m. from a healthy shift 
worker with no infection episode in the last 7 days. AIRLINE I included the blood samples 
taken in the lab during the working period and never from a participant after the night shift.  
AIRLINE (II). Out of 42 shift workers, described in the section above, we selected 32 shift 
workers aged 27-60 (22% women) with questionnaire data and blood samples collected 
twice. The first blood sample collection referred to the working period was performed as 
described in the section AIRLINE I. The second blood sample was collected in the lab in 
the morning from each participant after at least two weeks of vacation, with the same 
conditions of being healthy and with no episode of infection in the last 7 days. For the 
Publication II study we obtained paired blood samples and complete responses in the 
questionnaires for 32 participants.  
ADSLEEP. The ADSLEEP sample comprised twenty adolescent boys, with blood samples 
available for 17 individuals (age = 
time intervals from the clinical interviews used to assess depression symptoms and sleep 






other medications, b) did not have somatic conditions, and b) did not show any structural 
pathologies in the brain anatomy, according to brain magnetic resonance imaging (MRI).  
All studies were performed according to the principles of the Declaration of Helsinki. 
Sample collection and study designs were reviewed and approved by the appropriate ethics 
committees. All participants or their custodians provided written informed consent.  
4.1.2 Phenotypes 
Across all the studies, various sleep phenotypes were tested using case-control study design. 
Publication I was concerned with phenotypes “insufficient sleep” and “shift work disorder 
status”. Publication II aimed to compare individuals SWD versus healthy shift workers. 
Finally, Publication III comprised cases with both depression and sleep symptoms and 
healthy controls. Secondary analyses performed in the Publications II and III involved 
several additional phenotypes tested by applying correlation tests or in the association 
studies. 
Publication I. DILGOM sample was dichotomized based on the FINRISK survey question 
“Do you, in your opinion, sleep enough?” as described in Aho et al. [293]. Among 88 men 
aged 25-50, seventeen were deemed as cases suffering from insufficient sleep (answers 
“Seldom or almost never”), sixty-two formed a control group (answers “Yes, almost 
always” and “Yes, often”). We excluded nine men answering “I cannot say” and ended up 
with 79 men in total. At least one of the following symptoms were reported by all cases: 
insomnia during last month, short sleep defined as 6 hours or less or tiredness in the 
mornings. The majority of cases (94%) stated two or three of these sleep related symptoms, 
while among the controls, the majority (84%) reported none or one of them. 
Twenty-six AIRLINE men were divided into the SWD (cases) and non-SWD (controls) 
groups based on: a) questions estimating the shift type and evaluation of the working day-
specific symptoms of insomnia and sleepiness, and b) a three-week sleep diary and 
actigraphy monitoring to evaluate a reduction of total sleep time, as required by ICSD-3 
criteria [99]. Seventeen shift workers constituted SWD group reporting symptoms of 






total sleep time. Non-SWD group included nine men lacking significant insomnia and 
sleepiness.  
Publication II. For the paired methylome-wide analyses performed in the Publication II, 
SWD and non-SWD groups of AIRLINE cohort were defined in the same way as described 
earlier. Both genders were included in the study, totaling 32 shift workers (21 cases and 11 
controls). 
For the secondary analyses of recovery in SWD group, we used two questions from the 
questionnaire filled during work and vacation: (Q5) “How often do you not feel fresh after 
sleep?” and (Q6) “How often do you feel daytime sleepiness?” The following formula 
defined the change in recovery symptoms estimated for each of the 21 cases: 
CHANGE_SYMPTOMS = (Q5 + Q6)WORK – (Q5 + Q6)VACATION 
Three groups were established depending on the calculated value of 
CHANGE_SYMPTOMS: a well-recovered (n=10, value 2 or 3); recovered (n=5, value 1); 
poorly recovered (n=6, value 0 or -1).  
Similarly, we calculated the difference between the M-values measured during working 
period and vacation, as follows:  
CHANGE_METHYLATION = M-VALUEWORK – M-VALUEVACATION 
Publication III. The psychiatric evaluation of ADSLEEP participants was performed by a 
clinician using a semi-structured diagnostic interview, the Schedule for Affective Disorders 
and Schizophrenia for School-Age Children and Lifetime version (K-SADS-PL) [294]. 
Nine cases were confirmed to suffer either from a depressive disorder (n=8) or a circadian 
rhythm sleep disorder (n=1). None of them manifested psychotic features or was diagnosed 
with a bipolar disorder. None of the eight controls was diagnosed with Diagnostic and 
Statistical Manual of Mental Disorders (DSM) -IV axis I disorders. The sleep symptoms 
were assessed as part of K-SADS-PL interview attachment for affective disorders. Six items 
on sleep included initial insomnia, middle insomnia, terminal insomnia, sleep/wake rhythm 
disturbance, non-restorative sleep, and hypersomnia. All cases manifested clinically 
significant sleep symptoms and none of the controls did, as rated in the previous study [295].  
For the secondary analyses, the depressed mood was assessed using the shorter version of 






items. The insomnia symptoms were evaluated using self-reported questionnaire Athens 
Insomnia Scale (AIS) [297], while the tiredness was measured using the self-related 
Pediatric Daytime Sleepiness Scale (PDSS) [298].  In addition, the study included objective 
measures on sleep and vigilance.  
4.2 DNA methylation data  
In all studies, CpG methylation was performed using Infinium HumanMethylation450k 
BeadChip (Illumina, Inc., San Diego, California, USA). All samples were derived from 
peripheral blood, DNA extracted using standard laboratory methods, bisulfite converted 
using EZ DNA Methylation Kit (Zymo Research, Irvine, California, USA), as described in 
the manufacturer’s instructions, and assayed on the Illumina 450k array. We conducted 
post-array processing and normalization for all studies, as described in Karlsson Linnér et 
al. [299] 
DNA methylation data processing flowchart including preprocessing, quality control (QC) 
report, SWAN [185], exclusion of the probes [193], and generation of the support files 
including cell counts [192] is shown in Figure 9.  
 
 
Figure 9: Data preprocessing steps, according to R package minfi [208].  
Preprocess
• IDAT files read
• Background correction
QC 
• Deviant samples check, sex mismatch
• Exclusion of probes with detection P value > 0.01
• Ad hoc exclusion probes  (SNP, Sex chromosomes, 
CRP)
Normalization • SWAN normalization
Final data formats
• ~ 450K CpGs, M-values
• Cell counts (6 types)






After these steps, the final number of CpG probes numbered 479,953 (DILGOM), 433,479 
(AIRLINE I and II), and 439,128 (ADSLEEP). The methylome-wide analyses in all studies 
were conducted using M-values (log 2 ratio of the intensities of methylated probe versus 
unmethylated probe), as described in Aryee et al. [208]. 
4.3 EWAS models 
Publication I: we used multiple linear regression adjusted for covariates. 
Publication II: to estimate an effect of being on vacation (versus working) on 
each methylation site, we fit a linear least-squares model involving i) a group effect for both 
the SWD and control groups; ii) a vacation-vs-work specific effect for each group; and iii) 
the covariates. The significance of a vacation-specific effect, in either, each, or both groups, 
was evaluated using a variance ratio (F) test, while controlling for the between-group and 
covariates.  
Publication III: we used an empirical Bayes moderated t-test.  
Table 4 lists EWAS models for each study and corresponding covariates, where applicable.  
 






age, gender, alcohol, smoke, 
array, slide, 5 types of cells 
II SWD, time 32, 21/11 age, gender, alcohol, smoke, array 
III depression, sleep 17, 8/9 none 
 
Table 4: EWAS models used in Publications I-III. 
For each CpG probe, we acquired P value, FDR-corrected P value, hyper-or 
hypomethylation level defined from the value of the beta coefficient in the EWAS model, 







4.4 Bioinformatics analyses 
For the gene set enrichment analyses and pathways (I-III), an unranked list of gene names 
served as the input with the default settings for bioinformatics analyses. For the study of 
associated phenotypes (I), we selected the following key words as input to the Phenotype 
tool of Ensembl, to RGD, and to the UniProt: a) sleep, b) syndrome, and post-hoc we also 
added c) visual/retinal abnormalities added post-hoc. For the study of tissue specificity (II), 
we used the GENE2FUNC tool in FUMA exploiting GTEx v7 53 tissue types.  Table 5 
summarizes the bioinformatics tools used in the Publications I-III, as well as the methods 
of assessment of the statistical significance, and corresponding citations. 
 
Publication Tool Statistical significance Source 
I GO-based enrichment: GoMiner, 
Panther, g:Profiler 
Pathways: IPA 
Other: Ensembl release 90, RGD, 
UniProt 
FDR-corrected P < 0.05  
 






II Enrichr pathways: Reactome 2016 
Enrichr ontologies: GO 2018 
Other: FUMA, Ensembl, release 93 
FDR-corrected P < 0.05   
FDR-corrected P < 0.05   





III Pathways: IPA 
Other : Ensembl 
Uncorrected P < 0.05 [303], 
[304] 
 
Table 5: Bioinformatics tools used in Publications I-III. 
4.5 Statistical analyses and data visualization 
All statistical analyses in Publications I-III were done in R. Multiple testing correction was 
performed whenever needed using Benjamini-Hochberg (BH) correction method (EWAS, 
gene set enrichment analyses and pathways, correlation analyses) or Bonferroni method 
(FUMA, association studies). P value < 0.05 (after the multiple testing correction) was used 






uncorrected P value < 0.05 was defined as a threshold for a DMP. Correlation analyses (II) 
were performed using Spearman correlation. Statistical t-test (III) was two-sided. 
Association studies (III) involved linear regression model without covariates. The 
enrichment (a) and hypomethylation (b) scores (II) for the given Reactome 2016 pathway 
were calculated from the EWAS results, as follows: 
(a) N, DMPs / N, all 450K CpGs corresponding to the pathway genes, % 
(b) N hypomethylated DMPs / N, all 450K CpGs corresponding to the pathway genes, % 
Visualization of the results was performed using R packages: qqman, karyoploteR, RCircos 







5.1 DNAm pattern underlying insufficient sleep (I)   
To explore DNAm changes associated with insufficient sleep and SWD, we performed 
methylome-wide analyses in DILGOM, a population-based sample of 79 men (17 cases 
suffering from insufficient sleep), and in AIRLINE I, an occupational sample of 26 male 
shift workers (17 SWD cases). After the identification of significant CpGs with uncorrected 
P values < 0.05 (DMPs), we compared the results and found 720 DMPs common for both 
samples. Further analysis revealed the set of 317 genes (327 DMPs) that was subjected to 
the pathway analyses and to the study of genomic locations. A schematic illustration of the 










5.1.1 Loss of DNAm associated with loss of sleep 
The overlap set included 317 genes annotated to 399 DMPs common for both samples. The 
majority of these DMPs (78%, 248/317) were significantly hypomethylated in cases, as 
compared to the controls, suggesting that loss of sleep may be associated with the loss of 
methylation. 
5.1.2 Gene set ontology enrichment analyses 
To identify the affected biological pathways, we explored GO libraries in four online 
resources (GoMiner, Panther, g:Profiler) and in commercially available pathway analysis 
tool IPA (QIAGEN Inc.). The gene set enrichment analyses of 317 genes resulted in two 
major groups of pathways, with ”Nervous system development” (NSD) being common for 
all pathway tools. Table 6 lists the P values identified for two groups of pathways in four 
pathway tools and corresponding GO terms. 
 
 Nervous system development Cellular processes 
 GO:0007399 GO:0009987, GO:0044763 
GoMiner 0.039 0.014 
Panther 0.014 - 
g:Profiler 0.001 0.0015 
IPA 1.545E-5 - 
Table 6: Top results of the pathway analyses for 317 genes: numbers are FDR-corrected P values 
(GoMiner, Panther, g:Profiler) and uncorrected P value (IPA). 
 
The consensus NSD pathway included 89 genes (92 corresponding DMPs) after we 
removed the duplicates and unified the gene names in all pathway tools.  
5.1.3 The database search and study of the genomic locations 
To search for the additional information on the genes included in the overlap set, we 






GRCh38.p10). Of these 317 genes, 59 had no information about phenotype; 182 did not 
relate to any specific pathological condition; 19 were related to sleep or circadian rhythm, 
for example, sleep duration, sleep deprivation, chronotype or abnormal sleep behavior; and 
50 genes were associated with a genetic syndrome. After a close look at the genetic 
syndromes, we discovered that 13/50 syndromes involved some type of disturbances in 
visual processing, such as retinal abnormality, retinal dystrophy, retinitis pigmentosa or 
photoreceptor degeneration. Thus, we conducted an additional check in Ensembl and found 
eight genes which phenotypes were related with disturbances in visual processing. In total, 
we assessed 79/317 genes with phenotypic descriptions involving “sleep disturbance”, 
“circadian rhythm”, “visual disturbance”, and/or “genetic syndrome”.  
To inspect the genomic locations of these 79 genes, we created a circular representation of 
the genome (ideogram) and mapped these genes according to the chromosome location and 
phenotype groups (Figure 11). The ideogram revealed several clusters of DMPs on various 
chromosomes, out of which the most prominent one was located on chromosome 17 
comprising 15 genes. Other clusters were observed at the following chromosomal locations: 
1p36.12, 2p23.3, 3p21.31, 7q11.23, 11q13.1, and 19p12.  
The cluster located on chromosome 17 numbered fifteen genes, of which twelve have been 
earlier associated with SMS in rats or humans (ACLY, ANAPC11, AP2B1, BECN1, CPD, 
DCAKD, DLX4, DYNLL2, FAM195B, PCGF2, RAC, SLC9A3R1) and three genes related 
to retinopathies both in animals and humans (UNC119, CDK5R1, TSEN54), according to 








Figure 11. Circular representation of genome with mapped 79/317 genes. Genes marked in purple 
are associated with the sleep disturbances; in light grey – with disturbances in visual processing, in 
green – with both sleep and disturbances in visual processing. Genes marked in black are associated 
with the genetic syndromes. Red color shows genes located on chromosome 17. Figure is modified 
from my Master’s thesis, unpublished. 
5.2 DNAm pattern underlying recovery in shift workers (II)   
To investigate the DNAm changes resulted from being on vacation versus working period, 
we performed paired methylome-wide analysis in AIRLINE II, an occupational sample of 
shift workers including 32 individuals (7 women, 21 SWD cases). The strongest effect of 
vacation was discovered for the SWD group, with identified DMPs numbering 6.5% 
(28,419/433,479). Considering the remarkable effect of vacation in the group with SWD, 






analyses. We investigated the biological relevance of the top findings, using in-depth 
pathway analysis, and evidenced SWD-specific DNAm changes in the genes CREB1, 
GRIN2C, and CAMK2B that might be crucial for the recovery from the shift work. A 




Figure 12. Schematic of the study in Publication II. 
5.2.1 Restoration of DNAm associated with vacation 
We found the differences in the direction of genome-wide methylation in the SWD group 
versus control group: in SWD, 67% (290,430/433,479) of CpGs were significantly 
hypomethylated during working period as compared with vacation (40% in the control 
group). Among the DMPs, the percentage of the hypomethylated sites numbered 78 
(22,166/28,419), being 52 in the control group, proposing that vacation promoted 
restoration of DNAm in individuals suffering from SWD. 
5.2.2 Enrichment analyses of the vacation-sensitive gene set 
To explore the biological relevance of the top findings from the methylome-wide analysis 
in the SWD group, we ranked genes corresponding to the DMPs by the statistical 
significance (uncorrected P values). First 30 genes (uncorrected P value < 1E-5, FDR-
corrected P , identified as vacation-sensitive genes, served as input for the 
following enrichment analysis tools: FUMA [227] (tissue specificity), Enrichr GO 2018 






FUMA GTEx v7. Among the 53 specific tissue types available in GENE2FUNC tool, a 
significant enrichment at Bonferroni corrected P 
tissue “Substantia nigra”. Top three nominally significant results at uncorrected P value < 
0.05 included two other brain tissues “Amygdala” and “Hippocampus”. Altogether, we 
observed eight brain tissues among the top ten tissues with nominally significant 
enrichment, suggesting that the vacation-sensitive set may be differentially expressed in the 
brain. 
Enrichr Gene Ontology 2018. The enrichment analyses of the vacation-sensitive gene set 
performed in GO libraries “Biological Process”, “Molecular Function”, and “Cellular 
Component” agreed on the same biological process as the top finding – NMDA glutamate 
receptor complex/ activity. Table 7 summarizes top three findings ranked by the statistical 
significance (uncorrected P values) from each library.  
 
Name GO term 




GO Biological Process 2018    
excitatory chemical synaptic transmission GO:0098976 0.00004546 0.232 
calcium ion transport into cytosol GO:0060402 0.0003661 0.934 
excitatory postsynaptic potential GO:0060079 0.0003661 0.6227 
GO Molecular Function 2018    
NMDA glutamate receptor activity GO:0004972 0.00004546 0.05233 
ionotropic glutamate receptor activity GO:0004970 0.0002576 0.1483 
ligand-gated calcium channel activity GO:0099604 0.0004064 0.1559 
GO Cellular Component 2018    
NMDA selective glutamate receptor complex GO:0008328 0.00007779 0.03469 
ionotropic glutamate receptor complex GO:0034703 0.001557 0.3472 
cation channel complex GO:0034703 0.004266 0.6343 
 
Table 7: Top 3 results from GO 2018 libraries identified for the vacation-sensitive set of 30 genes 
in the SWD group. Highlighted in green is the GO term found statistically significant at P < 0.05 







Enrichr Reactome 2016. In-depth pathway analyses with Reactome revealed similar 
findings as we showed using GO libraries: top ten findings related to the activity of NMDA 
receptor. For each of the top ten Reactome pathways ranked by statistical significance, we 
calculated the DMP enrichment and hypomethylation scores in the SWD and control group. 
In SWD group, we found the highest DMP enrichment score of 8.3% (38/458) for the 
pathway “CREP phosphorylation through the activation of CAMKII” (further referred as 
“CREB-pathway”). Since Reactome pathways are organized in hierarchical structures 
[309], we were able to display specific molecular processes included in the parent NMDA-




Figure 13. Reactome 2016 hierarchical representation of pathways: starting from the parent term 
“Neuronal System” to the major finding identified in the SWD group “CREB phosphorylation 
through the activation of CAMKII”. Numbers are DMP enrichment scores calculated for SWD.  
 
CREB-pathway was specific for the SWD group, as the DMP enrichment score numbered 
4.1% (19/458) in the control group. We also observed hypomethylation in 74% of the DMPs 
in the SWD group, while in the control group the hypomethylation score was 26.3%. Thus, 
our findings evidenced that vacation may result in the specific DNAm changes in the genes 






5.2.3 Identifying putative DNAm biomarkers of recovery from SWD 
CREB-pathway identified at the previous step comprised 15 genes which corresponded to 
458 CpGs in Illumina 450K array. In SWD, we found 13/15 genes affected by vacation 
corresponding to 38 DMPs. We further investigated the correlations between methylation 
values (M-values) of these 38 DMPs and the degree of recovery (changes in SWD 
symptoms after the vacation). Three DMPs were found to correlate at P <0.05 (not 
significant after FDR-correction) with the degree of recovery: cg13823003 (GRIN2C), 
cg05019488 (CREB1), and cg18848222 (CAMK2B). Since these three sites showed the 
biggest absolute changes in the M-values for the shift workers with the highest degree of 
recovery from SWD, we proposed them as possible important indicators of a restoration of 
the healthy state. 
5.3 Studying adolescents with depression and sleep 
disturbances (III)   
5.3.1 Synaptic long-term depression pathway associated with depression 
and sleep disturbances in adolescents 
To investigate the effect of sleep disturbances and depression on DNAm, we performed 
methylome-wide analyses in ADSLEEP, a selected sample of 17 male adolescents (8 cases 
suffering from depression and sleep problems, 9 healthy controls). None of CpGs showed 
statistically significant difference in the methylation levels between cases and controls. We 
ranked the genes corresponding to the CpGs by the statistical significance (uncorrected P 
values) and selected top 500 DMPs (332 corresponding genes) with uncorrected P values < 
0.05 that differed the most between cases and controls. This list of genes served as input for 
the analysis of canonical pathways in IPA. Three canonical pathways reached statistical 
significance: “Synaptic long-term depression” (LTD) with uncorrected P value = 0.00045, 
followed by “NOS signaling in skeletal muscle cells”, and “Netrin signaling”, both with P 
values = 0.0042. The top canonical LTD pathway comprised ten genes: CACNG1, 
CACNG6, GRM6, IGF1R, ERK12, PLA2G16, PLA2R1, PPP2R5C, PRKG1, and RYR3. 
Among the corresponding CpGs, all but three (cg1684179 CACNG1, cg08364956 GRM6, 






5.3.2 Association studies between methylation levels of 10 LTP loci and 
symptoms of depression and sleep 
Ten CpGs corresponding to ten genes from the LTD pathway were included in the 
association studies aiming to explore the correlations between the M-values and symptoms 
of depression and sleep. The results of the linear regression analyses for five sites correlating 
at P <0.05 (significant after Bonferroni correction) are summarized in the Table 8.  
 
CpG (gene) Symptom (tool) Puncorr  Methylation 
cg12066398 (PLA2G16) depressed mood (BDI-19) 0.00031 hyper 
cg04367351 (PLA2R1) tiredness (PDSS) 0.00047 hyper 
cg05110803 (IGF1R) tiredness (PDSS) 0.00029 hypo 
cg25405123 (RYR) sleep (AIS) 0.00041 hyper 
cg02263165 (PPP2R5C) sleep (SWA dissipation) 0.004 hypo 
 
Table 8: Results from the linear regression secondary analyses in ADSLEEP. P values are 
uncorrected P values; methylation is referred as “hypo” standing for “hypomethylation” and 
“hyper” standing for “hypermethylation”; SWA, slow wave dissipation during 1st episode of the 
night.  
 
5.3.3 A comparative study of the results from ADSLEEP and AIRLINE II 
At last we explored ten CpGs corresponding to ten genes from LTD pathway identified in 
ADSLEEP, aiming to compare a) direction of methylation in SWD group (hyper or 
hypomethylation at work), and b) effect of vacation in SWD group (uncorrected P value 












ADSLEEP cases AIRLINE II SWD 
Gene CpG P  Methylation, cases P Methylation 
CACNG1 cg16841761 0.000381 hypo 0.036 hypo 
CACNG6 cg22025854 0.000527 hyper 0.877 hypo 
GRM6 cg08364956 0.000838 hypo NA NA 
IGF1R cg05110803 0.000306 hypo NA NA 
MAPK1 cg19161850 0.000663 hyper 0.039 hyper 
PLA2G16 cg12066398 0.000540 hyper 0.624 hyper 
PLA2R1 cg04367351 0.000659 hyper 0.909 hyper 
PPP2R5C cg02263165 0.000207 hyper 0.025 hyper 
PRKG1 cg18823846 0.000903 hyper 0.210 hyper 
RYR3 cg25405123 0.000427 hyper 0.243 hyper 
 
Table 9: Results from the cross-check of ten CpGs corresponding to ten genes from LTP pathway 
identified in ADSLEEP. P values are uncorrected P values; methylation in SWD group of 
AIRLINE II is referred to the data point “work” with “hypo” standing for “hypomethylation” and 
“hyper” standing for “hypermethylation”; two sites with NA were not assessed in the AIRLINE II 
sample due to the issues with quality control. 
 
Of the ten sites, eight were included in the AIRLINE II study and all but one (cg22025854 
CACNG6) showed the same direction of methylation. The significant effect of vacation at 
uncorrected P < 0.05 was observed for three sites: cg16841761 (CACNG1), cg19161850 







The three studies presented in this thesis aimed to explore DNAm modifications in blood 
leukocytes associated with sleep loss. In Publication I, we identified a distinctive 
methylation pattern in relation to subjective sleep insufficiency in a population cohort and 
in an occupational shift work sample of men. Publication II focused on the same shift work 
sample, but this study design involved paired data in combination with information from 
sleep diaries and questionnaires from both genders. The study enabled us to explore 
dynamic nature of DNAm during work and after the vacation, at the genome-wide scale. 
Publication III provided insights into the effects of disturbed sleep and depression on 
methylation patterns in adolescent boys compared to age-and gender-matched controls. 
Both Publication I and II investigate either self-reported or SWD-related insufficient sleep 
in cohorts of adults, while Publication III involves a case-control sample of young males 
with and without depressive disorder and comorbid insomnia and experiencing a crucial 
period of prominent changes in sleep patterns. As adolescence is characterized by sleep loss 
and circadian misalignments due to phase delay, this study allowed us to explore DNAm 
changes occurring in critical period of developmental changes. The findings of the three 
studies and their implications exemplify wide range of insights that can be obtained from 
the analysis of DNAm microarray data. 
The major finding of the first study is the hypomethylated set of 399 DMPs/ 317 genes that 
appeared to be common for both cohorts. The loss of methylation associated with a loss of 
sleep is concordant with a study of Bhatti et al., which observed significantly and 
consistently decreased DNAm in blood of nightshift workers compared to dayshift workers 
[245]. It is noteworthy that the effect of hypomethylation on transcription is difficult to 
estimate due to different kinds of CpG locations, i.e. promoter region or gene body. We 
found that among 317 genes, only 10% showed nominally significant correlations between 
methylation and gene expression levels indicating that possibly DNAm is just one of the 
epigenetic mechanisms regulating transcription.  
The observed pattern of 317 genes showed an enrichment of associations with the NSD 
pathway, which, according to GO database, comprises various processes underlying 
changes in nervous tissue. These processes include neurogenesis, synapse maturation, nerve 






with the DNAm study in brain tissues of rodents conducted by Massart et al., which showed 
that that DNAm changes in sleep-deprived animals occurred in genes involved in synaptic 
plasticity and neuritogenesis [25].  
The analysis of genomic locations of 317 genes led us to the discovery of several interesting 
clusters. One of them, located in chromosome 3, included genes associated with cellular 
responses to such stresses as hypoxia (LIMD1[310], SCAP[311]), DNA damage 
(CDC25A[312], NEK4[313]) and dietary K+ depletion (SLC38A3[314]). At least two earlier 
studies [315], [316] highlighted the association of sleep deprivation with cellular stress, and 
it is possible that we disclosed epigenetic mechanisms behind this association. A cluster in 
chromosome 7 comprised few genes related previously to autism and anxiety (STX1A[317], 
GTF21RD1[318], MAGI2[319]). A cluster possibly involved in regulation of transcription 
was located in chromosome 19 and included zinc finger transcription factors ZNF441, 
ZNF709, ZNF506, ZNF826, and ZNF43. Of 317 genes, we found 9 hypomethylated DMPs 
corresponding to zinc fingers and hypothesize that this the loss of methylation of 
transcription factors might be sleep-loss specific and contribute to overall changes in gene 
expression, as was noted in two transcriptome studies of insufficient [293] and mistimed 
sleep in humans [8].  
However, the most intriguing finding of the first study related to the cluster of 18 DMPs 
located in chromosome 17. In rodents twelve of these DMPs corresponded to genes earlier 
associated to SMS, a rare genetic disorder caused by mutations in RAI1 or more complex 
rearrangements of long arm of the chromosome 17 [320], [321]. RAI1 plays an important 
role in the regulation of circadian rhythmicity and its mutations in SMS patients are known 
to be responsible for the inversion of melatonin cycle [322]. The genetic variation in loci 
located within or near RAI1 were recently linked to OSA in men [323] and sleepiness in a 
large UK Biobank cohort [324]. Since one of the two studied cohorts in the first study 
consisted of shift workers suffering from SWD, we hypothesize that circadian 
misalignments, induced by the shift work, are connected to DNAm changes in the same 
regions in chromosome 17 that are involved in the melatonin disruptions of SMS. It is 
plausible to assume that region in chromosome 17 may play a role in the regulation of sleep 






The second study continued from the Publication I, incorporating a longitudinal aspect: here 
we studied DNAm methylation data in the same cohort of shift workers of both genders, 
with SWD and without, during work and after the vacation. We observed a prominent effect 
of vacation in the SWD group, indicating that firstly, a relatively small fraction of sites 
exhibits short-term dynamic changes across the genome, 6.5%. This number agrees with the 
earlier studies showing that human methylome is rather stable than dynamic and that only a 
small percentage of genomic CpG undergo dynamic changes in a non-pathological context 
[204], [205] . Secondly, the gain of sleep occurring during the vacation corresponded to the 
gain in methylation, and the DNAm restoration was more remarkable for the SWD group. 
Since our study, to the best of our knowledge, is the only longitudinal EWAS on recovery 
from a circadian sleep disorder, we could not compare our finding to other studies. We 
suggest that sleep restoration in shift workers may be accompanied by genome-wide DNAm 
increase but, importantly, our EWAS is restricted by the CpGs included in Illumina 450K 
and this finding cannot extend to the level of human methylome including 28 million CpGs.  
With the longitudinal design of the second study, we were able to narrow down a wide group 
of nervous system-associated pathways to the brain-specific pathways related to the activity 
of a glutamatergic NMDA receptor. The largest DNAm changes in relation to the degree of 
recovery in SWD group occurred in the genes from “CREB phosphorylation through the 
activation of CAMKII” pathway, including cAMP responsive element binding protein 1 
(CREB1), calcium/calmodulin dependent protein kinase II beta (CAMK2B), and glutamate 
ionotropic receptor NMDA type, subunit 2C (GRIN2C). The key players of CREB-CAMKII 
pathway belong to the Ca2+-dependent hyperpolarization pathway that earlier has been 
indicated in the regulation of sleep duration [325]. Several animal studies have shown that 
the activity of GRIN-subunits and CAMK-kinases is associated with the cortical capacity 
to evoke slow-wave oscillations, which is related to sleep length [326]-[328]. 
Based on the gene enrichment analyses and studies of recovery, we propose a mechanism, 
according to which recovery during vacation affects Ca2+-dependent hyperpolarization 
pathway (Figure 14). Furthermore, such vacation-induced changes in gene activity may be 
regulated via DNA methylation and involve specific CpGs in CREB1, CAMK2B, and 
GRIN2C. Thus, methylome of shift workers was affected by the two-week period of 
vacation, with distinct changes occurring in genes involved in the activity of NMDA 






The CpG sites in CREB1, CAMK2B and GRIN2C can serve as putatively important 
indicators of recovery in a shift worker with SWD symptoms. One of them, cg13823003 
from the CpG Island located at the promoter region of GRIN2C, demonstrated statistical 
significance through all our analyses and might be a particularly sensitive indicator of the 




Figure 14. The mechanism of vacation-induced changes in the CREB-CaMKII pathway underlying 
recovery in shift workers with SWD. The schematic depicts the changes at the DNAm level (white 
circles, hypomethylated DMPs, dark circles, hypermethylated DMPs) in CREB1, CAMK2B, and 
GRIN2C. Orange dots represent three DMPs identified in the correlation analyses with the degree 
of recovery (shallow circles, hypomethylated, orange circles, hypermethylated)).  
 
Publication III aimed to investigate the effect of sleep difficulties on DNAm in subjects 
suffering of sleep problems and depression. Though no genome-wide significant differences 
emerged from EWAS, we conducted pathway analyses for the top 500 sites that differed 
most between cases and controls. The top canonical pathway was the LTD pathway, with 
the largest DNAm changes in genes involved in the activity of calcium voltage-gated 






signaling kinases (ERK12, MAPK1, PRKG1) and phospholipases (PLA2G16, PLA2R1). The 
synaptic LTD pathway is essential for learning and memory consolidation and refers to the 
process of weakening of the individual synapses. Both LTD and LTP are linked to sleep in 
the synaptic homeostasis hypothesis proposed by Tononi and Cirelli [21] and contribute to 
memory consolidation. In rats, sleep deprivation can significantly increase LTD at 
glutamatergic synapses, with possible mechanisms of phosphatase activation, presynaptic 
regulation of glutamate release and postsynaptic glutamate receptor endocytosis [329], 
[330]. Publication III gave evidence that adolescent boys with sleep difficulties and chronic 
depression show changes in DNAm in the LTD pathway indicating compromised synaptic 
plasticity.  
Synaptic LTD pathway identified in the study of ADSLEEP is not defined in the Reactome 
2016 library; however, synaptic LTP pathway is situated under “Post NMDA receptor 
activation events”, neighboring CREB-pathway, along with several others. Considering 
both identified pathways might be related, we explored whether any of the CpGs identified 
in LTP pathway in ADSLEEP showed significant changes in AIRLINE II after the recovery 
period. Firstly, we observed the same direction of methylation for all but one CpG, 
indicating that for MAPK1, PLA2G16, PLA2R1, PPP2R5C, PRKG1, and RYR3 the 
hypermethylated CpG during sleep loss undergoes hypomethylation during the recovery 
phase. Secondly, three CpGs corresponding to CACNG1, MAPK1, and PPP2R5C replicated 
in the study of recover, suggesting that some of the genes associated with LTP might be 
involved in the recovery from sleep loss.  
Limitations. One of the obvious limitations of the three studies is the sample size. 
Publications I and III failed to yield genome-wide significant differences in methylation 
levels between cases and controls. However, in Publication I we combined the results from 
two independent cohorts matched by age and gender, which was a major strength of this 
study. In Publication III we conducted analyses in a carefully selected and homogenous 
sample of young, non-medicated boys and carried out careful clinical assessment of the 
cohort. Publication II used a relatively small sample of shift workers, with SWD status 







The second common limitation of the three studies is the use of blood samples for the study 
of sleep. DNAm is tissue-specific, so findings from blood leukocytes need to be interpreted 
with caution. However, sleep and circadian rhythms disturbances have a systemic effect on 
the human body, as described earlier [8], and all three studies agreed in the DNAm changes 
observed in brain-specific pathways, indicating that blood samples are informative source 
for changes induced by sleep loss. 
Publications I and III are conducted in the male samples which limits the generalizability of 
the results. Both sleep and DNAm are known to be largely affected by gender, therefore we 
limited out studies to the male gender in Publication I. Publication II included both genders 
and resulted in using gender as a covariate in EWAS.  
The fourth limitation, common for Publication II and III is the lack of gene expression data 
for AIRLINE and ADSLEEP.  The functional significance of the dynamic sites identified 
in Publication II is of a great interest and integrative analysis of DNAm and gene expression 
data would enhance our understanding of epigenetic regulation of gene expression. In 
Publication I we attempted to explore the correlations between DNAm level and gene 
expression and found a rather small fraction of sites with nominally significant correlations. 
No significant findings were observed once we explored the correlations between DNAm 
levels and gene expression in DILGOM gene expression data for three DMPs from 
Publication II and ten DMPs from Publication III. 
Conclusions and future prospects. The findings presented in this thesis shed light on some 
of the DNAm changes corresponding to sleep insufficiency and recovery from it. Many 
interesting aspects of this dynamic nature of human methylome still remain to be clarified.  
Both Publications I and III utilizing cross-sectional designs enabled us to show DNAm 
pattern in relation to subjective sleep insufficiency, and objectively assessed sleep 
difficulties in men. Both studies highlighted that lack of sleep is associated with DNAm 
alterations in brain-specific nervous system-related processes. The studies in well-powered 
independent cohorts or pooled data sets could improve our understanding of biological 
pathways behind insufficient sleep.  Publication II revealed the dynamic nature of these 
alterations, indicating that synaptic events occurring at glutamatergic NMDA receptor 
underlie the process of recovery from sleep debt. Prospective studies in larger cohorts, 






changes in the molecular processes of synaptic plasticity.  Investigations of the epigenetic 
changes associated with insufficient sleep may lead to the discoveries of important 
indicators of sleep loss in shift workers with circadian rhythm disturbances and may be of 
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Some common human diseases with studied DNAm patterns 
(Figure 5 in the main text) 
 
Autoimmune  
Rheumatoid arthritis  [1]-[9] 
Systemic lupus erythematosus  [10]-[16] 
Multiple sclerosis [17]-[24] 
Type 1 diabetes [25]-[30] 
Autoimmune thyroid disease  [31], [32] 




Cardiovascular disease [77]-[79] 
Myocardial infarction [80]-[83] 
Ischemic stroke [84]-[88] 
Coronary artery disease [89], [90] 
Atherosclerosis [91]-[95] 
Hypertension [96]-[98] 





Bipolar disorder [142]-[148] 
Schizophrenia [149]-[158] 
Psychosis [159]-[161] 
Post-traumatic stress disorder [162]-[166] 
Eating disorders [167]-[171] 
Personality disorders [172]-[175] 
  
Metabolic  
Type 2 diabetes [46]-[55] 
Obesity [56]-[61] 
Adiposity [62]-[64] 
Body-mass index (BMI) [65]-[68] 
Metabolic syndrome [69]-[71] 
Metabolic traits [72]-[76] 
Neurological  
Alzheimer’s disease [104]-[111] 
Parkinson’s disease [112]-[115] 
Amyotrophic lateral sclerosis [116], [117] 
Epilepsy [118]-[123] 
Pain [124]-[128] 
Migraine [129], [130] 
Chronic fatigue syndrome [131], [132] 
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